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ABSTRACT
Optimization and control theory are well developed techniques to quantize, model,
understand and optimize real world systems and they have been widely used in engi-
neering, economics, and science. In this thesis, we focus on applications in biomedical
systems ranging from cells to microbial communities, and to something as complex
as the human body.
The first problem we consider is that of medication dosage control for drugs de-
livered intravenously to the patient. We focus specifically on a blood thinner (called
bivalirudin) used in the post cardiac surgery Intensive Care Unit (ICU). We de-
velop two approaches (a model-free and a model-based one) that predict the effect of
bivalirudin. After obtaining the model and its best fit parameters by solving a non-
linear optimization problem, we develop automatic dosage controllers that adaptively
regulate its effect to desired levels. Our algorithms are validated using actual data
from a large hospital in the Boston area.
In the second problem, we introduce a cellular objective function inference mech-
anism in metabolic networks. We develop an inverse optimization method, called
vii
InvFBA (Inverse Flux Balance Analysis), to infer the objective functions of growing
cells by using their reaction fluxes. InvFBA can be seen as an inverse version of FBA
(Flux Balance Analysis) which predicts the distribution of the cell’s reaction fluxes
by using a hypothetical objective function. The objective functions can be linear,
quadratic and non-parametric. The efficiency of the InvFBA approach matches the
structure of the FBA and ensures scalability to large networks and optimality of the
solution. After testing our algorithm on simulated E. coli data and time-dependent S.
oneidensis fluxes inferred from gene expression data, we apply our inverse approach to
flux measurements in long-term evolved E. coli strains, revealing objective functions
that provide insight into metabolic adaptation trajectories.
In the final problem in this thesis, we formulate a novel resource allocation prob-
lem in microbial ecosystems. We consider a given number of microbial species living
symbiotically in a community and a list of all metabolic reactions present in the com-
munity, expressed in terms of the metabolite proportions involved in each reaction.
We are interested in allocating reactions to organisms so that each organism main-
tains a minimal level of growth and the community optimizes certain objectives, such
as maximizing growth and/or the uptake of specific compounds from the common
environment. We leverage tools from Flux Balance Analysis (FBA) and formulate
the problem as a mixed integer linear programming problem. We test our method
in a toy model involving two organisms that can only survive through cross-feeding,
demonstrating that the method can recover this interaction. We also test the method
in a community of two simplified bacteria described in terms of their core, simplified
metabolic network. We demonstrate that the method can obtain syntrophic cross-
feeding species that would be very difficult to design manually.
viii
Contents
1 Introduction 1
1.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Literature Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.3 Our Contributions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.4 Thesis Organization . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2 Predicting and Evaluating the Effect of Bivalirudin in Cardiac Sur-
gical Patients 7
2.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2 Regularized Regression . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.1 Preliminaries . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.2 The Predictors . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3 An Explicit Dynamic System Model . . . . . . . . . . . . . . . . . . . 18
2.3.1 The Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.3.2 Parameter Identification . . . . . . . . . . . . . . . . . . . . . 21
2.4 An Adaptive Model: Extended Kalman Filter . . . . . . . . . . . . . 24
2.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3 Adaptive Control of Bivalirudin in the Cardiac Intensive Care 30
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2 Dynamic System Model Formulation . . . . . . . . . . . . . . . . . . 31
3.2.1 The Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
ix
3.2.2 Parameter Identification . . . . . . . . . . . . . . . . . . . . . 33
3.3 Bivalirudin Control Scheme . . . . . . . . . . . . . . . . . . . . . . . 33
3.3.1 Model Reference Control (MRC) . . . . . . . . . . . . . . . . 35
3.3.2 Indirect Model Reference Adaptive Control (MRAC) . . . . . 41
3.3.3 Direct Model Reference Adaptive Control MRAC . . . . . . . 47
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4 Learning Cellular Objectives from Fluxes by Inverse Optimization 52
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.2 Inverse Process of FBA . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.2.1 Inverse FBA with Linear Objective Function . . . . . . . . . . 56
4.2.2 Linear Objective Variability Analysis . . . . . . . . . . . . . . 62
4.2.3 Inverse FBA with Quadratic Objective Function . . . . . . . . 63
4.2.4 Inverse FBA with Non-parametric Objective Function . . . . . 65
4.3 Numerical Examples . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.3.1 Inference of Linear Objective Functions in Simulated E. coli
Fluxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.3.2 Recovering Objectives and Fluxes From Noisy Data . . . . . . 71
4.3.3 Inference of a Linear Objective Function with Time-dependent
Fluxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.3.4 The Inference of Linear Objective Functions in E. coli Strains
that Underwent Long-term Evolutionary Experiments . . . . . 77
4.3.5 The Inference of a Quadratic Objective Function with Time
Series Fluxes . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
4.3.6 The Inference of a Kernelized Objective Function on E. coli Data 81
4.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
x
5 Optimal Allocation of Metabolic Functions among Organisms in a
Microbial Ecosystem 84
5.1 Problem Formulation . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.1.1 Community-level Flux Balance Analysis . . . . . . . . . . . . 86
5.1.2 Community Stoichiometric Partitioning . . . . . . . . . . . . . 90
5.2 An Artificial Toy Model . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.2.1 Model Description . . . . . . . . . . . . . . . . . . . . . . . . 91
5.2.2 FBA at the Community Level . . . . . . . . . . . . . . . . . . 92
5.2.3 Identification of the Putative Vector t . . . . . . . . . . . . . 94
5.3 A Simplified Bacterial Community . . . . . . . . . . . . . . . . . . . 95
5.3.1 Model Description . . . . . . . . . . . . . . . . . . . . . . . . 95
5.3.2 Community Analysis . . . . . . . . . . . . . . . . . . . . . . . 96
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
6 Conclusions 100
6.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6.2 Future Works . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
A LASSO Version of InvFBA 103
B Noise Generation 104
C Inference of Fluxes from Experimentally Measured Branching Ra-
tios 105
References 107
Curriculum Vitae 113
xi
List of Tables
2.1 Performance of the regularized polynomial regression (test set). . . . 18
2.2 Optimal parameters values. . . . . . . . . . . . . . . . . . . . . . . . 23
2.3 Performance of the dynamic system model. . . . . . . . . . . . . . . . 24
2.4 EKF vs. dynamic model. . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.1 Performance of the Model Reference Control (test set). . . . . . . . . 41
3.2 Performance of the Inaccurate Model Reference Control (test set). . . 42
3.3 Performance of the Indirect Model Reference Adaptive Control (test
set). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.4 Performance of the Direct Model Reference Adaptive Control (test set). 50
3.5 Performances of the three control laws (test set). . . . . . . . . . . . . 51
4.1 InvFBA results from `1 and `0 norm regularization of simulated E. coli
data under different growth conditions. . . . . . . . . . . . . . . . . . 70
4.2 InvFBA results from `1 and `0 regularization of simulated E. coli data
under different growth conditions (Maximization of ATP synthase). . 72
4.3 InvFBA results from `1 and `0 regularization of simulated E. coli data
under glucose minimal medium (Minimization of glucose uptake). . . 72
4.4 Inferred parameter values. . . . . . . . . . . . . . . . . . . . . . . . . 80
5.1 Biomass growth rate vs. the number of active reactions in the community. 97
xii
List of Figures
2·1 The inputs (predictors) and the output (response) of the regression
engine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2·2 Performance of the regularized polynomial regression for d = 1 and
d = 2 for different numbers M of time series inputs in the test set. . . 17
2·3 The single-state linear model includes a gain, 1/β3, representing the
elimination time constant of bivalirudin from the body. The constant
β2 provides for the translation from serum concentration to the site-
effect (PTT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2·4 Illustrating the performance of the dynamic system model of Sec-
tion 2.3 for a particular patient. The blue “o” represent predicted PTT
values from our model and the red “∗” represent actual measured values. 21
2·5 Illustrating the performance of the EKF algorithm for a particular
patient. The blue “o” represent predicted PTT values from our model
and the red “∗” represent actual measured values. The top figure plots
estimated and measured PTT and the bottom figure plots the running
RMSE at each step. Additionally, blue dot line represents the average
RME of EKF adaptive method while green dot line represents the fixed
parameters solve by previous section. It is obvious that EKF adaptive
methods fits the individual model better. . . . . . . . . . . . . . . . . 25
2·6 The EKF algorithm for recursively estimating model parameters for
an individual patient. . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
xiii
2·7 Illustrating the evolution of model parameter values z = (β1, . . . , β13, x(0))
during the course of EKF algorithm. . . . . . . . . . . . . . . . . . . 27
3·1 In this dynamic model, the bivalirudin infusion rate u(t) is the only
controllable input. d(t) is the linear combination of the rest of the inputs. 33
3·2 Model Reference Adaptive Control (MRAC) structure. . . . . . . . . 34
3·3 The effect of the MRC law derived for and applied to one randomly
selected patient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3·4 The MRC law derived for one patient but applied to another patient. 41
3·5 The performance of the indirect MRAC law. . . . . . . . . . . . . . . 44
3·6 The performance of direct MRAC law. . . . . . . . . . . . . . . . . . 48
4·1 The feasible set of the FBA problem is a polyhedron – the intersection
of points satisfying the linear constraints of (4.1). xj, j = 1, . . . , 4,
denote extreme points of the feasible set. Depending on the objective
function coefficient c, one of these extreme points is optimal. In some
cases, a particular c can lead to multiple extreme points being optimal
(purple case), in which case the whole edge/facet containing them is
optimal. Notice, that for each optimal extreme point there are many
c’s that could have led to its optimality. These “valid” c’s belong to a
cone (cf. the four colored cones drawn). . . . . . . . . . . . . . . . . 54
xiv
4·2 (Left): The union of these cones is all of Rn (n = 2, in the figure). If
we use an `2-norm regularization in the invFBA formulation, “valid”
c’s lie on the surface of the unit ball in Rn. (Right): Illustration of the
geometric intuition behind `2-regularized FBA. The FBA feasible poly-
hedron can be partitioned using bisector lines. In this 2-dimensional
example, the polyhedron is partitioned by 4 bisectors into 4 (colored)
polytopes. For example, if the observed flux distribution x lies in the
yellow polytope then c1 is the corresponding objective function. If,
however, the observed flux distribution lies in the bisector between the
blue and the yellow region, invFBA will yield either c1 or c4. . . . . . 58
4·3 (Left):A simple simulated metabolic network model with a single metabo-
lite A and three reactions. (Right): We plot the FBA polyhedron on
the x1–x2 plane. The red dot indicated a given metabolic flux distri-
bution. The invFBA algorithm yields c = (1/3, 2/3). . . . . . . . . . 62
xv
4·4 This diagram illustrates concisely the flow of information for invFBA
calculations in this work. The right part of the figure displays schematic
representations of the set of metabolic fluxes. Each flux vector can also
be visualized on a metabolic chart (right-most part of the figure), where
gray arrows of different thicknesses indicate different intensities of re-
action fluxes throughout a network. The left part of the figure displays
instead the space of metabolic objectives. Coefficients of the objective
function can also be visualized on a metabolic chart (left-most part of
the figure), with red arrows representing non-zero components of the
objective. (A) FBA uses a given objective function (here cgrowth) to
predict a set of fluxes (XOpt), or multiple equivalent sets of fluxes (not
shown). From one FBA solution one can use InvFBA to infer possible
objective functions. The solution is not necessarily unique, though the
space of possible solutions can be rigorously characterized, and con-
tains the original objective function. (B) InvFBA can be applied to
multiple (noisy) experimental measurements of fluxes, leading, as in
the test case of panel A, to a space of possible objective functions. . . 69
4·5 The maximal value of the biomass coefficient cbiomass, found by in-
vFBA and subsequent Objective Variability Analysis (OVA), is plotted
as a function of the level of noise (σ2) in FBA-simulated flux data for
E. coli. These FBA-simulated fluxes are produced using maximiza-
tion of biomass production as the objective function. Thus, a value of
cbiomass close to unity in OVA indicates that invFBA recovers the orig-
inal objective. As the levels of noise increases, however, the capacity
of recovering the original objective is highly reduced. . . . . . . . . . 73
xvi
4·6 Metabolite secretion flux (dashed line), inferred from experimental
data through the TEAM approach, and maximum coefficient of the
pyruvate secretion flux in the objective function (full line), as predicted
by invFBA (through OVA), are plotted as a function of time. Metabo-
lite and gene expression data come from time-dependent measurements
performed during batch aerobic growth of the bacterium S. oneidensis
on lactate. The secreted metabolites are pyruvate in Fig. 4·6a, gly-
colate in Fig. 4·6b, and acetate in Fig. 4·6c. Positive fluxes reflect
secretion of the metabolite in question, while negative fluxes reflect
uptake. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4·7 (A) Experimental measurements (by (Harcombe et al., 2013)) of ac-
etate excretion and glucose uptake for the ancestral (red star) and
evolved (blue and red dots) E. coli strains from Lenskis long-term
evolutionary experiment. The red and blue colors are used here to
highlight two distinct metabolic regimes that different strains seem to
cluster around. (B) A projection (onto a two dimensional subspace)
of the set of objective functions compatible with experimentally mea-
sured fluxes. The graph is obtained through a two-dimensional version
of OVA: for each possible value of the growth flux coefficient of the ob-
jective function (cBiomass), one can find the minimal and maximal value
of the objective function coefficient for the respiratory flux (cRespiration),
obtaining areas that correspond to objective functions compatible with
the measured fluxes. Such regions can be computed for the ancestral
and all evolved E. coli strains. The strains corresponding to the dif-
ferent metabolic regimes (blue and red dots in (A)) map onto different
regions in the space of objectives, labeled with similar colors. . . . . 78
xvii
4·8 Simulation flowchart for the inference of a nonparametric objective
function. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4·9 Performance evaluation of the nonparametric objective function. . . . 83
5·1 The structure of the universal stoichiometric matrix S. Block Su rep-
resents the set of uptake reactions used to absorb nutrients from the
environment. Blocks [Se1; Se2] represent the set of exchange reactions
between external and internal metabolites. Si represents the set of
internal reactions among internal metabolites. . . . . . . . . . . . . . 87
5·2 The structure of the stoichiometric matrix for the whole community
Sc ∈ RMc×Nc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5·3 The structure of the artificial community with two different organisms.
Both organisms 1 and 2 uptake the same external metabolite (EX)
from the environment. Organism 2 produces Y only via R1 and obtains
Z from organism 1. Organism 1 produces Z only via R2 and obtains
Y from organism 2. Organisms 1 and 2 have the same biomass growth
reaction which involves X, Y and Z. Organisms 1 and 2 cannot grow
without each other. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
5·4 The universal stoichiometric matrix S. The rows of S include three ex-
ternal metabolites (EX,EY,EZ) and three internal metabolites (X, Y, Z).
The columns of S include one uptake reaction, three exchange reac-
tions, and three internal reactions. . . . . . . . . . . . . . . . . . . . . 93
xviii
5·5 The community stoichiometric matrix Sc is shown in the top figure.
The binary vector t denotes the ground truth, consistent with Fig. 5·4.
The optimal flux distribution x∗ is shown in the bottom. To distinguish
the internal metabolites in the two organisms, we use X1, Y 1 and Z1
to denote the internal metabolites in organism 1, and X2, Y 2 and Z2
for the internal metabolites in organism 2. . . . . . . . . . . . . . . . 93
5·6 The results of identifying t∗ and the corresponding flux vector x∗. They
are consistent with the ground truth in Fig. 5·5. . . . . . . . . . . . . 95
5·7 The universal stoichiometric matrix S and the corresponding flux vec-
tor by maximizing the biomass growth rate for an individual bacterial
model from (Covert et al., 2001) under the current growth conditions. 96
5·8 Visualization of the outcome of our algorithm, applied to a model of
generic bacterial central carbon metabolism from (Covert et al., 2001).
In this case, the algorithm is applied to two organisms that have the po-
tential to contain all 12 internal reactions found in the initial network.
Yet, the algorithm identifies two distinct species with fewer internal
reactions that perform different tasks, but can collectively achieve all
the metabolic functions necessary for growth. . . . . . . . . . . . . . 98
xix
List of Abbreviations
ALB . . . . . . . . . . . . . Albumin
ATP . . . . . . . . . . . . . Adenosine triphosphate
BFGS . . . . . . . . . . . . . Broyden Fletcher Goldfarb Shanno
EHRs . . . . . . . . . . . . . Electronic Health Records
EKF . . . . . . . . . . . . . Extended Kalman Filter
FBA . . . . . . . . . . . . . Flux Balance Analysis
ICU . . . . . . . . . . . . . Intense Care Unit
INR . . . . . . . . . . . . . International Normalized Ratio
InvFBA . . . . . . . . . . . . . Inverse Flux Balance Analysis
LASSO . . . . . . . . . . . . . Least Absolute Shrinkage and Selection Operator
LTI . . . . . . . . . . . . . Linear Time Invariant
LV . . . . . . . . . . . . . Lotka Volterra
MILP . . . . . . . . . . . . . Mixed Integer Linear Programming
MPP . . . . . . . . . . . . . Maximum Power Principle
MRAC . . . . . . . . . . . . . Model Reference Adaptive Control
MRC . . . . . . . . . . . . . Model Reference Control
NRSME . . . . . . . . . . . . . Normalized Root Mean Square Error
PLT . . . . . . . . . . . . . Platelet Count
PTT . . . . . . . . . . . . . Partial Thromboplastin Time
R2 . . . . . . . . . . . . . the Real plane
RKHS . . . . . . . . . . . . . Reproducing Kernel Hilbert Space
RRT . . . . . . . . . . . . . Resource Ratio Theory
RSME . . . . . . . . . . . . . Root Mean Square Error
SGOT . . . . . . . . . . . . . Serum Glutamic Oxaloacetic Transaminase
SGPT . . . . . . . . . . . . . Serum Glutamic Pyruvic Transaminase.
TBILI . . . . . . . . . . . . . Total Bilirubin
xx
1Chapter 1
Introduction
1.1 Overview
Optimization and control theories are essential to any problems involving decision
making and resource allocation. The primary goal of decision making is to choose the
best solution among various alternatives. The measure of goodness is determined by
an objective function (Chong and Zak, 2013). Control theory is an interdisciplinary
branch of engineering and has found many application in several domains. It deals
with the behavior of dynamic systems with inputs, and how their behavior is regulated
by feedback. The most common objective is to control a system so that its output
follows a desired signal. The optimization and control techniques have been widely
applied to the fields of computer science, management science, biology, and many
others.
In recent years, the optimization and control theories have received more and
more attention, primarily because of the increasing availability of data and the rapid
progress in computer technology. Due to the advantages of optimization and control
theories, computational algorithms become more efficient and deeper insights behind
the “big data” are revealed. In this thesis, we focus on the novel applications of opti-
mization and control theories in biomedical systems, ranging from cells to microbial
communities, to the human body. In the biomedical field, new modeling techniques
and quantitative methods can to improve healthcare efficiency, interpret the metabolic
mechanisms and design synthetic organisms, which has the potential to bring great
2benefits to society.
1.2 Literature Review
In the past decades, researchers have never stopped exploring the field of biomedical
systems by conducting experiments, analyzing data, and developing new models.
Optimization and control theories have very important roles to play in this area of
research. One of the motivations for new research is that the US health care system
is considered costly and highly inefficient. While there is no broad agreement on the
potential solutions, the meaningful use of Electronic Health Records (EHRs) is seen as
a key to improving efficiency. The health care system, however, is not well equipped
to deal with the impeding deluge of personalized health-related EHRs and medical
devices. EHRs and the digitization of data from medical devices have the potential
to aid prevention, automate decision making, and facilitate treatments. Motivated
by these, researchers focus on leveraging the EHRs to develop models so that they
can be used for improving healthcare efficiency. For example, (Edrich et al., 2011b)
and (Edrich et al., 2011a) propose a simple steady-state linear model to describe the
effect of bivalirudin in cardiac surgical patients. In (Dai et al., 2015), optimization
and supervised machine learning theory are applied to predict the hospitalization
due to cardiac diseases using actual EHRs data. In (Ludwick and Doucette, 2009),
several mathematical methods are introduced to analyze and to model the clinical
data. These advanced clinical data analysis methods improve the efficiency of the
health care system and bring significant benefits to both hospitals and patients.
At the micro biology level, optimization and control methods not only explain
current adaptations of biological systems, but also help to predict new designs that
may yet evolve. Linear programming is used to analyze metabolic networks and to
predict the internal fluxes of an individual cell in (Kauffman et al., 2003). In (Sauer
3et al., 1998), a non-convex optimization method is applied to infer the cells’ objective
functions under certain growth conditions. In (Segre, 2008), a non-linear optimiza-
tion approach is adopted to develop the constraints based metabolic regulation model
and to identify the corresponding regulation effect matrix. (Heinrich and Schuster,
1998) leverages the ideas of dynamic systems in control theory to model the dy-
namic metabolic system and analyze its controllability and optimality. (Heinrich and
Rapoport, 1974) utilizes the dynamic system to describe a linear steady-state treat-
ment of enzymatic chains. (Newsholme and Crabtree, 1979) leverages the properties
of extreme points in linear optimization theory to find and to interpret the extreme
pathways in the metabolic network. With these advanced models and methods, the
structures of the metabolic systems can be described unambiguously, and predictions
about their behaviors can be made in a systematic way.
Based on the well-developed models of the individual cells, researchers extended
their attention to the synthetic ecology which involves design, construction and inter-
pretation of microbial communities. Despite the growing availability of experimental
data for a diverse range of complex natural microbial communities, the full char-
acterization and understanding of these communities is still challenging (Zomorrodi
and Segre`, 2016). To solve this problem, efficient computational techniques and
mathematical modeling tools are required. These models are critical in interpreting
ecological and evolutionary questions (e.g., quantifying the inter-species interaction,
environment factors on the cooperation, coexistence of cooperators and cheaters in
the communities, etc.). The most important role of mathematical modeling is that we
are able to rationally design and simulate synthetic consortia for desired applications.
Two of the most important models in theoretical ecology are Resource Ratio Theory
(RRT) and the Maximum Power Principle (MPP). RRT (Miller et al., 2005) has been
primarily used to model competition and has been extended to account for cooperative
4interactions as well. MPP (Miller et al., 2005) relies on the assumption that all biolog-
ical systems self-organize to increase power. A traditional way to model the dynamics
of microbial communities rooted in theoretical ecology is the use of coupled differen-
tial equations describing the temporal evolution of microbial species abundances. The
most widely-used such model is the Lotka-Volterra (LV) model (Wangersky, 1978).
The complex balancing of benefits and costs associated with inter-species interactions
in microbial communities can also be effectively addressed by using game theory and
evolutionary game approaches (Schuster et al., 2008). Flux Balance Analysis (FBA)
(Harcombe et al., 2013) is a widely used approach for studying biochemical networks,
and in particular the genome-scale metabolic network reconstructions. The problem
of predicting a cell’s chemical reaction fluxes is formulated as the linear optimization
problem of maximizing a cellular objective (e.g., growth) subject to constraints cap-
turing stoichiometry mass balances of the metabolic network and bounds that reflect
the composition of the growth medium.
1.3 Our Contributions
In this dissertation, we first describe an automated decision making system that
can be used to control medication dosing in the ICU. In this work, we develop an
automated bivalirudin infusion system targeted for cardiac surgical patients in the
ICU. To achieve this goal, we develop two approaches that predict the effect of bi-
valirudin. The first approach is model-free and utilizes regularized regression. The
second approach is model-based and leverages more detailed biomedical knowledge.
After obtaining the model and its best fit parameters, we develop three adaptive
dosage controllers that regulate bivalirudin’s effect to desired levels under different
cases. Our algorithms are validated by using the actual clinical data.
In the second part of the thesis, we focus on inferring the cell’s performance-based
5on the experimentally observed fluxes under certain growth conditions. Towards
this goal, we develop an inverse Flux Balance Analysis (invFBA) method which is a
novel convex optimization based framework. The convexity of the invFBA approach
matches the structure of the (forward) FBA and ensures scalability to large networks
and optimality of the solution. Within this framework, we present three different
forms of objective functions: linear, quadratic, and non-parametric. We show that in
all cases, the inverse problem is tractable and can be solved efficiently. We also provide
several numerical examples to evaluate the performance of invFBA and interpret the
results from both biological and mathematical aspects.
In the third part, we extend our scope from the individual cells to microbial
ecosystems. We develop a novel Mixed Integer Linear Programming (MILP) based
approach to optimally allocate the metabolic functions among organisms in a mi-
crobial ecosystem. We test the method on both a toy artificial community and a
community composed of two bacterial organisms with a simplified core metabolism.
In both cases, the method helps us identify the individual metabolic network topology
and elucidate the interaction between species in the microbial community. It offers
a new platform for the rational design of organisms and communities towards future
synthetic ecology applications.
1.4 Thesis Organization
The remainder of this thesis is organized as follows.
• Chapter 2 introduces the automatic decision system of bivalirudin. It describes
a model-free regularized regression method first and then presents the dynamic
system model and the model-based parameter identification method. The ex-
tended Kalman filter is used to achieve model parameter adaptation.
• Chapter 3 presents our novel convex optimization based method –Inverse Flux
6Balance Analysis (InvFBA)– which is used to infer the objective function of a
cell under certain growth conditions. We apply the invFBA to different data
sets and interpret them from different aspects.
• Chapter 4 provides a mixed integer linear programming-based approach to op-
timally allocate metabolic reactions among organisms in a microbial ecosystem.
• Chapter 5 includes concluding remarks and introduces an outline of future work.
Notation: We use bold letters to denote vectors and matrices; vectors are denoted
by lower case letters and matrices by upper case letters. Vectors are assumed to be
column vectors unless explicitly stated otherwise. For economy of space we write x =
(x1, . . . , xn) for the n-dimensional column vector x ∈ Rn. Prime denotes transpose,
|| · || denotes the Euclidean norm, 1 (resp., 0) denotes a vector or matrix with all
components set to one (resp., zero), and diag(x) denotes a diagonal matrix with the
main diagonal being the vector x and all other off-diagonal elements being zero.
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Predicting and Evaluating the Effect of
Bivalirudin in Cardiac Surgical Patients
2.1 Background
Bivalirudin antagonizes the effect of thrombin in the blood clotting cascade, thereby
preventing complications from blood clotting. It is currently FDA-approved for short
term anticoagulation of patients undergoing cardiac catheterization to prevent com-
plications due to undesired blood clots (Bittl et al., 2001; Lincoff et al., 2003; Stone
et al., 2006). Bivalirudin is infused as a “blood thinner” in patients who have or
are suspected of having blood clots or risk of blood clotting and who have a con-
traindication to heparin. It is infused continuously, and is eliminated via the kidney
and by plasma protease-metabolism. It affects the coagulation parameters Partial
Thromboplastin Time (PTT) and the International Normalized Ratio (INR) in a
dose-dependent fashion. Both measure the ability of the blood to clot but while PTT
is measured in seconds, INR is a dimensionless number. Clinically, PTT can be seen
as the key effect of bivalirudin and the level of PTT highly depends on the dosage of
bivalirudin and patients’ renal and liver conditions.
As a rarely used drug, bivalirudin is used more frequently in the Intensive Care
Unit (ICU) but residents adjusting the infusion rate may have little experience, re-
sulting in overdosing or underdosing. Adequate anticoagulation is necessary to avoid
the risk of clot formation, but overshooting increases the risk of bleeding. There is
8considerable inter- and intra-individual variability in the response to bivalirudin; it is
challenging to titrate the drug. Currently, empiric titration of bivalirudin according
to clinical experience or a simple nomogram is used to achieve desired anticoagulation
(Kiser et al., 2011). For this reason, a mathematical model that predicts the PTT
based on the past infusion rates of bivalirudin following dose adjustment would be
useful to guide optimal therapy.
In earlier work ((Edrich et al., 2011b) and (Edrich et al., 2011a)), an one-state
linear system model to describe the effect of bivalirudin in patients has been proposed.
The models were designed using Matlab/simulink (Mathworks, Natick, MA) and de-
fault parameter identification procedures. Motivated by this work, in the present
chapter we develop two new methods to predict PTT values based not only on past
bivalirudin infusion rates but also on a host of patient-specific physiological vari-
ables that characterize coagulation, renal, and liver function. The results we obtain
substantially improve accuracy compared with the earlier work.
Our first method is model-free, in the sense that a specific model does not need to
be constructed in advance, and leverages regularized and kernelized regression. With
uniform sampled data, standard time series analysis methods (e.g., ARX, ARMAX
(Hannan and Deistler, 1988)) could have been a viable alternative. In our problem, we
encounter highly non-uniform sampled data which challenges the standard methods,
hence our use of regularized regression. Our method is purely data-driven and requires
no explicit model to explain how bivalirudin affects PTT. It is flexible enough to
use several samples of bivalirudin infusion rates from the immediate past in order
to predict current PTT values. Since we use a rich set of predictors, we devise a
regularization approach that can eliminate unnecessary predictors and regress on a
reduced predictor set so as to avoid overfitting.
Our second method develops a more complex explicit dynamic state space system
9model than the one developed in ((Edrich et al., 2011b) and (Edrich et al., 2011a)).
This new model takes the elimination of bivalirudin by the kidneys and the liver
into account. We identify model parameters by formulating a nonlinear optimization
problem that minimizes the `2 norm of prediction error over a training set of measure-
ments. As we mentioned before, we only have highly non-uniform sampled real data.
Furthermore, the dosage of bivalirudin given to patients should be carefully titrated
to ensure patient safety. As a result, we can not observe PTT values in response
to arbitrary dosage. This suggests that canonical state-space system identification
techniques (e.g., adaptive system identification (Ioannou and Kosmatopoulos, 2006),
subspace state space system identification method (Ljung, 1987)) are not applicable.
The nonlinear optimization problem we formulate is solved by leveraging quasi-
Newton methods. The dynamic system model we obtain performs only somewhat
worse than the model-free approach, even though it uses a shorter history of past
measurements. Building on this model, we develop an adaptive on-line algorithm
based on the extended Kalman filter than can adapt the model parameters to indi-
vidual patients. The algorithm starts from population-wide optimal parameters and,
as it observes inputs and outputs, modifies model parameter values to better fit an
individual patient. This adaptive model outperforms the model-free method in terms
of average prediction error, despite using a shorter history of past measurements. This
confirms the empirically known considerable individual variability in the response to
bivalirudin. Further, with the adaptive model, the per-patient error variability is
substantially reduced compared to the population-wide dynamic system model and
it is on par with the corresponding error variance of the model-free method.
The approaches we put forth in this work are general and can be applicable to a
host of related problems. As ICUs and hospital wards accelerate the digitization of
patient records, tremendous opportunities arise for automated and mathematically
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rigorous patient monitoring and medication dosing. It is in such a framework that
the methods we develop can become useful.
The remainder of the chapter is organized as follows. Section 2.2 presents the
model-free regularized regression method. Section 2.3 presents the dynamic system
model. Section 2.4 develops the extended Kalman filter to achieve model parameter
adaptation. Finally, concluding remarks appear in Section 2.5.
2.2 Regularized Regression
In this section we present our first “black box” approach. The idea is to use regression
with appropriate function regularizers that can help avoid overfitting. We start with
some preliminary material on regularization and then describe the features we use
and the results we obtained.
2.2.1 Preliminaries
For completeness and to establish our notation we review standard material on regu-
larized regression from (Zou and Hastie, 2005) and (Hastie et al., 2009). Let x ∈ Rp
denote the vector of features or predictors and y ∈ R the output or response. Suppose
we are given a training set (xi, yi), i = 1, . . . , N , and we are interested in selecting a
function f : Rp → R from some space H so that it approximately holds yi ≈ f(xi)
over the training set. To that end, we can adopt a loss function L(y, f(x)) that
quantifies the quality of the fitting and solve the optimization problem
min
f∈H
{ N∑
i=1
L(yi, f(xi)) + λG(f)
}
, (2.1)
where G(f) is a regularization term that penalizes functions from H which are not
smooth enough, and λ is a parameter that determines the contribution of the penalty
term. The purpose of the regularization term is to induce smoother functions that
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do not have too many changes, and thus help avoid overfitting. The parameter λ can
be selected by cross-validation as we will explain later.
An important special case concerns functions that live in a so called Reproducing
Kernel Hilbert Space (RKHS) HK . For some (positive semi-definite) kernel function
K(x, z), x, z ∈ Rp, written as
K(x, z) =
∞∑
j=1
γjφj(x)φj(z),
where φj(·)s are basis functions which can be any popular functions (e.g., polynomial,
Gaussian, cosine and so on) and the scalars γj ≥ 0 satisfy
∑∞
j=1 γ
2
j <∞, the functions
f ∈ HK can be written as
f(x) =
∞∑
j=1
cjφj(x).
The regression problem (2.1) can now be written as
min
f∈HK
{ N∑
i=1
L(yi, f(xi)) + λ‖f‖2HK
}
, (2.2)
where the regularizer is the norm in HK defined as ‖f‖2HK =
∑∞
j=1 c
2
j/γj. According
to the Representer theorem (Scho¨lkopf et al., 2001), the solution to this problem has
the form
f(x) =
N∑
i=1
αiK(x,xi), (2.3)
and, in light of this form, finding the parameters αi becomes as easy as solving a
finite-dimensional optimization problem. If in fact one assumes a nice structure for
the loss function, e.g., squared loss L(y, f(x)) = (y − f(x))2, then there are very
efficient algorithms for finding the αi. In the case of squared loss, all we need to do
is solve a simple convex unconstrained quadratic optimization problem which admits
a closed-form solution.
The choice of the kernel is important but very much dependent on the particular
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application one has to tackle. In our problem, a polynomial kernel achieves lower
prediction error than alternatives. A polynomial kernel is of the form K(x, z) =
(x′z + 1)d, for x,y ∈ Rp and some integer d, which is the sum of all monomials∏p
i=1 x
dxi
i z
dzi
i with d
x
i , d
z
i = 0, 1, . . . , d such that
∑p
i=1 d
x
i ≤ d and
∑p
i=1 d
z
i ≤ d.
2.2.2 The Predictors
In our problem, we have clinical data from 233 patients. The key quantity (response)
we would like to predict is the Partial Thromboplastin Time (PTT) yi(t) of each
patient i at each time t. As predictors we include 11 key physiological variables
sampled over M consecutive time instants t > t − τ1 > · · · > t − τM−1 where τm for
m = 1, . . . ,M − 1 denote the time lags between consecutive measurements. These
time lags are included as the 12th predictor.
The 11 physiological variables are:
1. Bival rate (mg/kg/h): the weight-based Bivalirudin injection rate.
2. GFR (mL/min): the Glomerular filtration rate, reflecting the ability of the
kidneys to eliminate bivalirudin. Decreased GFR would increase the serum
level of bivalirudin and the PTT in an approximately linear fashion (Company,
2011).
3. PTT (s): last measured partial thromboplastin time.
4. INR (Unit-less): the last measured international normalized ratio which is a
coagulation time that is distinct, but associated with the PTT. This increases
as the serum level of bivalirudin increases.
5. SGOT (Units/L): the Serum Glutamic Oxaloacetic Transaminase, and
6. SGPT (Units/L): the Serum Glutamic Pyruvic Transaminase. Increasing SGOT
and SGPT would reflect liver dysfunction and decreased production of clotting
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Figure 2·1: The inputs (predictors) and the output (response) of the
regression engine.
factors, thus increasing PTT which, in turn increases with liver dysfunction.
Since the liver produces clotting factors, liver dysfunction will increase the PTT.
7. TBILI (mg/dL): total bilirubin, a “waste product” normally eliminated by the
liver. In liver dysfunction, this is positively associated with a rising PTT.
8. ALB (g/L): Albumin, which reduced in the setting of liver failure and therefore
associated with a rising PTT.
9. PLT (K/mcL): Platelet count. Platelets help form blood clots with clotting
factors from the liver. They are utilized when a clot is formed. A decreas-
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ing platelet count can indicate ongoing clotting with consumption of clotting
factors, thus, elevating the PTT and INR.
10. HCT (%): Hematocrit. HCT is a measure of the amount of red blood cells
in the blood. When patients loose blood during operations and other non-
operative bleeding, then fluids such as normal saline are provided to make up
for the blood volume lost. This, however, lowers the HCT. At the same time,
the added volume dilutes the clotting factors in the blood and causes PTT and
INR to increase.
11. FIB (mg/dL): Fibrinogen. This protein helps produce clots and its decreased
concentration may indicate that clotting is occurring. It follows that clotting
factors are being depleted which will cause elevated PTT and INR.
Let now xphi (t) ∈ R11 denote the vector containing the 11 physiological variables
presented above for patient i at time t. Note that xphi (t) contains PTT and INR
values at time t− τ1. To predict yi(t) we will use the predictor vector
xi(t) = (x
ph
i (t), τ1,x
ph
i (t− τ1), . . . , τM−1,xphi (t− τM−1)), (2.4)
that is, M consecutive measurements of xphi (t) and the corresponding time lags which
forms a (12M − 1)-dimensional vector.
Our regression engine uses a polynomial kernel K(x, z) = (x′z + 1)d which can be
written in terms of its (orthonormal) eigenfunctions, say asK(x, z) =
∑J
j=1 φj(x)φj(z),
where J is the number of eigenfunctions. For our polynomial kernel it holds J =(
12M−1+d
d
)
. The response function takes the form f(x) =
∑J
j=1 cjφj(x). We write
φ(x) = (φ1(x), . . . , φJ(x)). We formulate a slightly different problem than (2.2) in
that we use the so called elastic net penalty (Zou and Hastie, 2005). More specifically,
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we minimize over the coefficients c = (c1, . . . , cJ) the expression
N∑
i=1
∑
t=ti
[yi(t)− c′φ(xi(t))]2 + λ1
J∑
j=1
c2j + λ2
J∑
j=1
|cj|, (2.5)
where N henceforth represents the number of patients in the training set and the
summation over ti is over the time instances in which we have measurements for
those patients. The difference with (2.2) is the addition of a penalty term equal to
the `1 norm of c. This is done to induce sparsity and eliminate features that are
“redundant” and not helpful in predicting yi(t). In our experiments, we found that
it was important to include such a sparsity-inducing penalty especially because we
use multiple time instances from the past to predict the current PTT value. Notice
that the objective function in (2.5) is convex, thus, this problem can be easily solved
using standard optimization techniques. The parameters λ1 and λ2 can be tuned
using cross-validation as we will describe next. We also note that before solving (2.5)
we standardized the predictors to have zero mean and unit variance.
2.2.3 Results
We randomly split the data into 3 sets of equal size. The first two sets are used for
training and the third set for testing. To select optimal values for the parameters λ1
and λ2 in (2.5) we use leave-one-out 6-fold cross-validation applied to the training set
(the first two sets). More specifically, we subdivide the training set into 6 equal parts.
For a discretized collection of (λ1, λ2) we train (i.e., solve (2.5)) on the first 5 parts
and use the 6th part to compute the prediction error (i.e., the first term in (2.5)).
This is done for each 1
6
th of the data left out of training and used only for validation
and we then compute the average of the corresponding 6 prediction errors. We use
this average value to select the best (λ1, λ2). With values of (λ1, λ2) now fixed we
resolve (2.5) on the whole training set and determine which cj’s are (close to) zero.
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We eliminate the corresponding features and then solve once more a simple regression
problem (i.e., a problem with just the first term in (2.5)) on the whole training set
using only the features that were not eliminated. This yields a final vector c and a
prediction
yˆi(t) = c
′φ(xi(t)), (2.6)
for each patient i and time t. The reason for performing a simple regression with the
non-eliminated features is that (2.5) naturally biases coefficients cj towards smaller
values.
For performance evaluation, we use two performance metrics. The first is the Root
Mean Square Error (RSME), which for patient i is defined as
RMSEi =
√
1
Ti
∑tTii
t=t1i
(yˆi(t)− yi(t))2, (2.7)
where t1i , . . . , t
Ti
i are the time instants at which we make a PTT prediction for patient
i.1 We define RMSE for the whole population of patients as the average per patient
RMSE, i.e., RMSE = 1
Nt
∑Nt
i=1 RMSEi, where Nt is the number of patients in the test
set. We also define σRMSE to be the standard deviation of the RMSEi values, which
captures the variability of RMSEi from RMSE.
To capture a notion of “relative” error we also compute the Normalized Root Mean
Square Error (NRMSE) defined for each patient i as
NRMSEi =
√
1
Ti
∑tTii
t=t1i
[(yˆi(t)− yi(t))/yi(t)]2. (2.8)
As with the RMSE, we define the population-wide NRMSE as the average of NRMSEi
over the patients and σNRMSE as the standard deviation of the NRMSEi values.
Starting with the prediction in (2.6), we explored two instances of polynomial
1We note that since we use a history of M −1 measurements for the prediction at time t, we only
make predictions starting from the Mth available measurement for each patient.
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kernels corresponding to d = 1 and d = 2 and also varied the length M which
determines how far back in time we go to define the feature vector. We used again
6-fold cross-validation over the training set and plot the results in Figures 2·2 for
kernel parameters d = 1 and d = 2, respectively. From the figures it follows that for
each case there is an optimal value for M , which is M = 5 for d = 1 and M = 4
for d = 2. This make intuitive sense. As we increase M , the performance initially
improves since the predictors provide more information but after some value of M
the performance deteriorates due to overfitting.
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Figure 2·2: Performance of the regularized polynomial regression for
d = 1 and d = 2 for different numbers M of time series inputs in the
test set.
Finally, and for these two kernels and corresponding optimalM values, we evaluate
the performance of the prediction given by (2.6) on the test set, that is, the 1
3
rd of
the data isolated from the training set in the beginning. Table 2.1 reports the results.
It follows that the linear kernel performs better. We should note that the quadratic
kernel achieves slightly less RMSE than the linear kernel on the training set (cf.
Figs. 2·2) but apparently it overfits and the performance is not as good in the test
set.
In summary, a key advantage of the regression method we presented in this section
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Table 2.1: Performance of the regularized polynomial regression (test
set).
d = 1 d = 2
RMSE 11.54 18.69
σNRMSE 4.04 5.37
NRMSE 21.44% 36.58%
σNRMSE 6.33% 9.82%
is that it does not require any understanding of the mechanism by which bivalirudin
affects PTT values for patients. The next section explores whether a specific model
can provide better performance.
2.3 An Explicit Dynamic System Model
This section introduces a Multiple Input Single Output (MISO) dynamic system model
that attempts to explicitly account for the way bivalirudin affects PTT values in
patients.
2.3.1 The Model
The dynamic system model is shown in Fig. 2·3. It seeks to represent how bivalirudin
acts in a single generic patient and uses as inputs the exact same physiological vari-
ables used as predictors in Section 2.2.3. In the absence of established quantitative
models to relate most of the input variables to PTT, a simple linear model was
assumed. Moreover, most of these variables change slowly over time and were mea-
sured infrequently (e.g., once per day) in the data we analyzed. As a result, they
were modeled without a dynamic component.
To make things more precise, in this dynamic system, there are 11 inputs which
are denoted by ui(t), i = 1, . . . , 11, and correspond to the physiological variables of
Section 2.2. We note that for ease of notation, we will suppress the patient identifier in
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Figure 2·3: The single-state linear model includes a gain, 1/β3, rep-
resenting the elimination time constant of bivalirudin from the body.
The constant β2 provides for the translation from serum concentration
to the site-effect (PTT).
our generic model description. The input u1(t), in particular, denotes the bivalirudin
infusion rate, and the remaining inputs correspond to the physiological variables 2–
11 detailed earlier. These inputs capture the patient’s indicators of renal and liver
function. There is only one output – the PTT value – which is denoted by y(t). There
is also a single state variable denoted by x(t). The model has 14 unknown parameters:
13 of which correspond to the various gains and are denoted by βi, i = 1, . . . , 13. The
initial condition of the system is the 14th unknown parameter and is denoted by
x(0). We will refer to z = (β1, . . . , β13, x(0)) as the parameter vector. In order to
be consistent with the medical intuition and avoid the overfitting issues, upper and
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lower bounds will be introduced for some of the parameters.
Let us denote u(t) = (u1(t), . . . , u13(t)). The system dynamics can be expressed
as follows:
x˙(t) = Ax(t) + Bu(t), (2.9)
y(t) = Cx(t) + Du(t),
where A = −β3, B = [β1 0 · · · 0], C = β2, and D = [0 β4 · · · β13]. Clearly, this
is a Linear Time Invariant (LTI) dynamic system. The challenge is that we only
have sampled input, u(t), and observation values, y(t), at certain times t for each
patient. It is therefore needed to translate the continuous-time system dynamics to
discrete-time dynamics.
Using a standard conversion from continuous to discrete time dynamics in LTI
systems (see e.g., (Friedland, 2012)) we can write
x(t+ τ) = eAτx(t) +
t+τ∫
t
eA(t+τ−s)Bu(s)ds, (2.10)
where in our case eτA = e−β3τ . Assuming u(s) = u(t) for s ∈ [t, t+ τ ] and after some
algebra we arrive at the following discrete-time dynamics:
x(t+ τ) = e−β3τx(t) +
β1
β3
(1− e−β3τ )u1(t), (2.11)
y(t) = β2x(t) +
∑13
i=4 βiui−2(t).
These equations characterize a discrete-time LTI system for which we have a history
of sampled input and output values. Next we describe how the training set can be
used to identify the unknown parameters, namely, the initial condition x(0) and the
parameters βi, i = 1, . . . , 13.
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2.3.2 Parameter Identification
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Figure 2·4: Illustrating the performance of the dynamic system model
of Section 2.3 for a particular patient. The blue “o” represent predicted
PTT values from our model and the red “∗” represent actual measured
values.
As we did in Section 2.2, we randomly split our data set of 233 post-cardiac surgical
ICU patients into a training set corresponding to 2/3 of the total (155 patients) and
a test set corresponding to 1/3 of the total (78 patients). We will use the former to
identify the unknown system parameters and the latter to evaluate the performance
of the resulting model.
Let us use a subscript j to denote the model primitives, i.e., the state xj(t), output
yj(t), and inputs uj(t) for each patient j = 1, . . . , N , where N denotes the number
of patients in the training set. To distinguish between measurements of yj(t) and
predictions based on the system dynamics (cf. (2.11)) we use yj(t) for the former
and yˆj(t) for the latter. Suppose for each patient j we have Tj measurements at
times t1j , . . . , t
Tj
j , where we adopt the convention t
0
j = 0 for all j. Using the discrete-
time system dynamics from (2.11), we formulate the following nonlinear optimization
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problem in order to identify the unknown system parameters:
min
∑N
j=1
∑tTjj
t=t1j
(yˆj(t)− yj(t))2
s.t. xj(t
n
j ) = e
−β3(tnj −tn−1j )xj(tn−1j )
+ β1
β3
(1− e−β3(tnj −tn−1j ))uj,1(tn−1j ),
∀j = 1, . . . , N ; n = 1, . . . , Tj,
yˆj(t
n
j ) = β2xj(t
n
j ) +
∑13
i=4 βiuj,(i−2)(t
n
j ),
∀j = 1, . . . , N ; n = 1, . . . , Tj,
x(0) is free,
βm ≤ 0, m = 1, 2, 3, 5, 7, 8, 9,
βn ≥ 0, n = 4, 6, 10, 11, 12, 13,
(2.12)
where the decision variables are x(0)(= x(t0j) for all j) and the parameters βi, i =
1, . . . , 13. One can easily substitute the expressions from the constraints into the
objective function and obtain a simple nonlinear optimization problem with the only
remaining constraints being bounds on some decision values. Using counterexamples,
it can be shown that the objective function obtained in this manner is not convex in
the decision variables.
Although a lot of methods exist for nonlinear optimization problems, we used
the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method (Bertsekas and Bertsekas,
1999), which is considered the most effective general purpose quasi-Newton method.
Quasi-Newton methods are gradient methods of the form
zk+1 = zk + αkdk, dk = −Dk∇f(zk),
where f(·) denotes the objective function, zk the decision variables at the kth iter-
ation of the method, αk is the stepsize at the kth iteration, and Dk is a positive
definite scaling matrix that scales the gradient at the kth iteration. Rather than
determining Dk by computing a Hessian and inverting it, which is computationally
expensive, quasi-Newton methods recursively estimate the inverse of the Hessian by
using successive iterates of zk and ∇f(zk).
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We solved (2.12) on the training set using BFGS and obtained the optimal solution
shown in Table 2.2. To avoid getting stuck at shallow local minima, which is possible
in the absence of convexity, we used a multi-start approach, namely, we started BFGS
from multiple randomly selected initial points and selected the best local minimum we
obtained. Using the optimal parameters from Table 2.2, we evaluated the performance
of the prediction on the test set and obtained the results shown in Table 2.3. It can be
seen that the performance is somewhat worse than the one obtained with polynomial
regression. This suggests that the simple model we devised in this section does a
decent job of capturing the key effect of bivalirudin. It uses just a single state and, as
it can be inferred from (2.11), the prediction at time t depends on the inputs u(t) at
t, and the state-input pair, x(t−τ) and u(t−τ) at the previous time instant t−τ . In
contrast, the best result with polynomial regression was obtained with a linear kernel
but a history of inputs going back 4 consecutive time instants. One can of course
devise a more complicated model that uses more memory, we elected not to pursue
this direction in the interest of simplicity and taking into account that the potential
difference in performance that is to be gained would not be big.
Table 2.2: Optimal parameters values.
index name value
1 k dist 57.39
2 k coag 59.74
3 1/T 60.00
4 kGFR −2.65× 10−7
5 kINR 0.77
6 kPTT 3.13
7 kSGOT 4.66× 10−7
8 kSGPT 2.70× 10−4
9 kTBILI 0.21
10 kALB −4.23× 10−6
11 kPLT −7.59× 10−8
12 kHCT −4.36× 10−7
13 kFIB −4.16× 10−8
14 x(0) 0.61
To further illustrate how well the predictor matches the measured values, we plot
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Table 2.3: Performance of the dynamic system model.
Metric Value
RMSE 14.65
σRMSE 6.2
NRMSE 26.42%
σNRMSE 11.04%
in Fig. 2·4 predicted and actual PTT values over time for a particular randomly
selected patient.
We note that the solution shown in Table 2.2 is obtained from a training set con-
taining data from many patients and thus corresponds to optimal “population-wide”
parameters. The signs of these parameters are consistent with medical intuition. It
can be seen that some parameter values are quite small, yet, their presence improves
the dynamic model performance; eliminating them will lead to worse performance. In
addition to providing a simple model that explicitly models the effect of bivalirudin,
the work in this section has additional benefits. As we will see next, having an explicit
model allows us to adapt model parameters to better fit each individual patient.
2.4 An Adaptive Model: Extended Kalman Filter
In this section we focus on an arbitrary individual patient and seek a method to
adapt the parameters of the model we proposed in Section 2.3 in order to better fit
this particular patient. To that end, we view the model parameters as the “states”
of a system and the output y(t) as a nonlinear function of that state. We devise a
recursive method to estimate the state. Due to the nonlinearity of y(t) we use the
Extended Kalman Filter (EKF) (see e.g., (Welch and Bishop, 2006)).
Let us denote the state of the system by z = (β1, . . . , β13, x(0)), which are exactly
the model parameters we want to estimate. We assume we have measurements of the
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Figure 2·5: Illustrating the performance of the EKF algorithm for a
particular patient. The blue “o” represent predicted PTT values from
our model and the red “∗” represent actual measured values. The top
figure plots estimated and measured PTT and the bottom figure plots
the running RMSE at each step. Additionally, blue dot line represents
the average RME of EKF adaptive method while green dot line repre-
sents the fixed parameters solve by previous section. It is obvious that
EKF adaptive methods fits the individual model better.
inputs u(t) and the PTT values y(t) over many time instants. We will index these time
instants by k, with k = 0 corresponding to t = 0 and k = 1, 2, . . . , T corresponding to
the time instants t1, . . . , tT at which we have measurements. (Notice we use the same
notation as in Section 2.3 but suppress the index j used there to identify a patient.)
We view the state z as being invariant over time and not affected by noise, while the
output y depends on z but is subject to some noise due to both measurement noise
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1. Initialization:
(a) Set zˆ0|0 = (β1, . . . , β13, x(0)) using the values obtained by solving the
population-wide problem (2.12), and
(b) set P0|0 = I.
2. Predict:
(a) zˆk+1|k = zˆk|k;
(b) Pk+1|k = APk|kA′.
3. Update:
(a) Kk+1 = Pk+1|kC′(CPk+1|kC′ + σ2)−1;
(b) zˆk+1|k+1 = zˆk+1|k + Kk+1(yk+1 − h(zˆk+1|k));
(c) Pk+1|k+1 = (I−Kk+1C)Pk+1|k.
Figure 2·6: The EKF algorithm for recursively estimating model pa-
rameters for an individual patient.
and model error. We can therefore write the (discrete) system dynamics as:
zk = zk−1, (2.13)
yk = h(zk) + νk.
In the above, h(·) is a known nonlinear function that expresses yk as function of the
parameter vector zk and uk,uk−1, . . . ,u0, x0 as specified by the dynamics in (2.11).
The random variable νk represents the noise and we assume it is i.i.d. over time, zero
mean Gaussian, with variance σ2, that is νk ∼ N(0, σ2) for all k.
Let A = I, and C = ∇h′(zk). The EKF algorithm is given in Fig. 2·6, where
“hat” denotes the estimate, P the error covariance, and K the Kalman gain.
To demonstrate the effect of this algorithm, we randomly selected a patient who
has adequate sample data and applied the EKF algorithm of Fig. 2·6 (using σ2 =
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Figure 2·7: Illustrating the evolution of model parameter values z =
(β1, . . . , β13, x(0)) during the course of EKF algorithm.
0.006). The results are shown in Fig. 2·5. It is evident that after some initial steps,
the algorithm “learns” better values for the model parameters than the ones in the
population-wide model and produces better predictions for this particular patient.
The model parameter values for the same patient during the course of the EKF
algorithm are shown in Fig. 2·7. It can be seen that they do “adapt” over time from
the initial population-wide values to values that are more appropriate for this patient.
To test the performance of the algorithm on a larger set of patients, we selected
patients with enough samples; in particular, more than 60 data points. There are 19
out of 78 patients in our set with more than 60 data points. We applied the EKF
(using again σ2 = 0.006) with the optimal population wide parameter values as our
initial point. By doing so, “warming process” of the EKF can be reduced significantly
and we have a decent model even at the early steps; the latter being important for
patient safety. In contrast, if we use an arbitrary initial point, the EKF takes at
least 25 steps for the parameter values to stabilize. Moreover, the model error in
these early steps becomes quite large which is unacceptable in an eventual use of our
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system in clinical practice.
Table 2.4 reports average results from the EKF algorithm applied to the patients
in the reduced test set of 19 patients described in the previous paragraph. RMSE and
NRMSE are computed on a per-patient basis and then averaged over these patients.
By testing the same subset of the original test set with EKF and the dynamic model,
we notice that NRMSE improves by 22.23% (4.73% in 21.28%), which is significant.
More details are shown in Table 2.4. This confirms the significant individual patient
variability in response to bivalirudin which has been only empirically observed.
Further more, the EKF algorithm leads to improved performance even in com-
parison to the model-free method of Section 2.2 which, as we have discussed, uses a
longer history of past measurements. In particular, NRMSE improves by 23% while
the variance stays about the same.
Table 2.4: EKF vs. dynamic model.
Metric EKF Dynamic
RMSE 8.61 11.36
σRMSE 3.28 3.29
NRMSE 16.55% 21.28%
σNRMSE 6.90% 5.8%
2.5 Conclusions
We have developed two main approaches to predict the effect of bivalirudin in cardiac
surgical patients. The first approach is model-free and leverages regularized regression.
We find that a linear kernel performs best and that the corresponding set of predictors
uses a collection of physiological variables characterizing bivalirudin infusion rate,
several coagulation indicators, and indicators of renal and liver function sampled over
a set of four time instances before the time at which a PTT prediction is sought.
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Namely, this model-free method uses a history of four prior feature vectors to make
a PTT prediction.
Our second approach is model-based and constructs a specific model that captures
how bivalirudin affects PTT values. The model uses a shorter history of prior fea-
ture vectors than the model-free approach in order to arrive at a prediction. Model
parameter identification is done by solving a nonlinear optimization problem over a
training set. The model-based approach produces somewhat worse performance than
the model-free one, which is understandable given the shorter history used.
The model-based approach, however, enables the development of an adaptive ex-
tended Kalman filtering algorithm that can adapt model parameters to individual
patients. This approach produces best average performance and a variance which is
almost identical to the model-free method. Compared to the population-wide opti-
mal dynamic model, NRMSE is reduced by 22.23%. This shows that patient-specific
models have significant advantages over population-wide models.
The mathematical models and prediction approaches described in this study may
provide a better reference to guide the optimal therapy in cardiac patients in need
of bivalirudin. In addition, such mathematical ideas and methods may be useful to
test medication dosing strategies and may provide a mathematical mechanism for
development and testing of nomograms. In the next chapter, we will introduce three
different adaptive control laws to obtain the optimal dosage.
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Chapter 3
Adaptive Control of Bivalirudin in the
Cardiac Intensive Care
3.1 Introduction
In previous chapter, we developed two methods for predicting future PTT values
given past infusion rates and the patient’s renal and liver function characteristics.
We proposed an explicit dynamic system model which was shown to produce quite
accurate results when tested against actual patient data. In this chapter, we pursue
what we view as the natural next step. Leveraging the dynamic system model from the
previous chapter, we seek to synthesize controllers that can regulate the infusion rate
to drive PTT within a desirable range. Other methodologies such as expert systems
have also been used for controlling some drugs (Held and Roy, 1995). We develop
two types of control laws. First, assuming that a dynamic system model that can
predict PTT given dosage is completely characterized, we develop a Model Reference
Control (MRC) law. Model parameters, however, may be viewed as not known with
certainty, which is due to modeling errors and inter- or intra-individual variability.
To overcome this problem, we develop an indirect Model Reference Adaptive Control
(MRAC) law that identifies the model parameters first and then adapts the controller
in real-time. Furthermore, we develop a direct Model Reference Adaptive Control law
that adapts the controller directly without estimating model parameters first, which
is more efficient. For each case, we present analytical and numerical evidence showing
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that the controllers do drive PTT to the desirable range. Our numerical validation is
in fact done using actual patient data from the Brigham and Women’s Hospital – a
large hospital in the Boston area.
The remainder of the chapter is organized as follows. Section 3.2 presents the dy-
namic system model that predicts the effect of bivalirudin given dosage and patient
physiological information. Section 3.3 presents the proposed control schemes; Sec-
tion 3.3.1 develops the MRC law whereas Section 3.3.2 develops the indirect MRAC
law based on the patient model but with unknown parameters. Section 3.3.3 devel-
ops the direct MRAC, which is more efficient in adapting the controller. Finally,
concluding remarks appear in Section 3.4.
3.2 Dynamic System Model Formulation
3.2.1 The Model
This section presents a Multiple Input Single Output (MISO) dynamic system model
that attempts to explicitly account for the way bivalirudin affects PTT in patients.
The model was developed and validated in Chapter 2, Section 2.3; it is presented
here briefly to establish the notation and to set the stage for the control schemes of
Section 3.3.
The key quantity (response) we would like to predict is the PTT at each time t.
The dynamic model structure is shown in Fig. 2·3. There are 11 inputs which are
denoted by ui(t), i = 1, . . . , 11 and correspond to important physiological variables
used as predictors. More specifically, inputs u1(t), . . . , u11(t) respectively correspond
to:
1. Bival rate (mg/kg/h): the weight-based bivalirudin injection rate.
2. GFR (mL/min): the glomerular filtration rate.
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3. PTT(s): last measured PTT value.
4. INR(unit-less): last measured INR value.
5. SGOT (Units/L): the Serum Glutamic Oxaloacetic Transaminase.
6. SGPT (Units/L): the Serum Glutamic Pyruvic Transaminase.
7. TBILI (mg/dL): total bilirubin.
8. ALB (g/L): Albumin.
9. PLT (K/mcL): Platelet count.
10. HCT (%): Hematocrit.
11. FIB (mg/dL): Fibrinogen.
More detailed description of these physiological variables can be found in Chapter 2,
Section 2.3.
The model of Fig. 2·3 has a single output –the PTT value– which is denoted
by y(t). There is also a single state variable denoted by x(t). Overall there are 14
unknown parameters: 13 of which correspond to the various gains and are denoted by
βi, i = 1, . . . , 13. The initial condition of the system is the 14th unknown parameter
and is denoted by x(0) (β14). The system dynamics are:
x˙(t) = Ax(t) + Bu(t), (3.1)
y(t) = Cx(t) + Du(t),
where A = −β3, B = [β1 0 · · · 0], C = β2, and D = [0 β4 · · · β13]. Clearly, this is a
Linear Time Invariant (LTI) dynamic system. The challenge is that we do not know
the model parameters and we only have non-uniform sampled inputs u(t), and clinical
observation values y(t) at certain times t for each patient. It is therefore necessary
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to translate the continuous-time system dynamics to discrete-time dynamics before
proceeding with parameter identification.
3.2.2 Parameter Identification
Given the highly non-uniform sampled data, two methods were introduced to identify
model parameters in Chapter 2, Section 2.3.2. First, after converting to discrete-
time dynamics, we formulated the parameter identification problem as the nonlinear
optimization problem of minimizing some metric of fitness to a training set of sampled
data. This yielded a population-wide model in the sense that its parameters produced
the best fit with the sampled data. Furthermore, and to accommodate variability
across patients, we used a recursive estimation method (Extended Kalman Filter) to
estimate the parameter values that best fit a given individual patient in real-time.
3.3 Bivalirudin Control Scheme
Figure 3·1: In this dynamic model, the bivalirudin infusion rate u(t)
is the only controllable input. d(t) is the linear combination of the rest
of the inputs.
We now turn to our goal of devising a proper controller to keep the PTT value in
the range of 60s-80s. According to clinical experience, this range is safe and optimal
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Figure 3·2: Model Reference Adaptive Control (MRAC) structure.
for cardiac surgery patients. For the system we have defined in Eq. (3.1), note that
the only controllable part is the bivalirudin infusion rate. The rest of the inputs are
indicators of patients’ liver (SGOT, SGPT, TBILI, ALB) and renal function (GFR)
and include some metrics related to the blood (PLT, HCT, FIB). Arguably, these
variables are not immediately affected by the drug but change over a longer time-
scale than the one we focus on for controlling PTT through the infusion of bivalirudin.
Therefore, we consider them as non-controllable and aggregate them in a variable d(t)
which is their linear combination with the appropriate gains β4, . . . , β13 (see Fig. 3·1).
Ideally, we want to design a reference model which can generate sufficient but safe
PTT values driven by a reference input signal. Based on the output of the reference
model, we want to drive our system to perform similarly to the reference model by
a proper control signal. Motivated by this, we adopt the so called continuous-time
MRAC scheme. Fig. 3·2 shows the general structure of this control law. Wm(s)
denotes an ideal reference transfer function that can generate the desired reference
output signal. The controllable system is represented by Gp(s,θ
∗
p), where θ
∗
p is a
parameter vector. The objective is to design a controller C(s,θ∗e), parameterized by
θ∗e, to generate the proper control signals that can drive the controllable system to
track the reference output values.
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Our first controller is an MRC law that is designed assuming that the system
parameters θ∗p are known.
3.3.1 Model Reference Control (MRC)
By observing the system in Fig. 3·1, we can rewrite the dynamics of a particular
patient as
x˙p(t) = −β3xp(t) + β1u(t), (3.2)
yp(t) = β2xp(t) + d(t), (3.3)
where we use u(t), xp(t), yp(t) to denote the input signal (bivalirudin infusion rate),
the state variable, and the output signal (PTT), respectively, and where d(t) =∑11
i=2 βi+2ui(t). Clinically, since the renal/liver functions and blood metrics of pa-
tients do not vary much within a certain period, we do not need to measure these
physiological variables continuously and we assume that they are constant within the
sample interval. By observing the clinical data, we find that d(t) is a step-wise signal.
Therefore, we assume that the first order derivative of d(t) (d˙(t)) is 0 within the sam-
ple interval. By taking the derivative on both sides of (3.3), using (3.2) to substitute
for x˙p(t), and using (3.3) to eliminate x˙p(t), we obtain:
y˙p(t) = −β3yp(t) + β1β2u(t) + β3d(t). (3.4)
In the frequency domain, we have
Yp(s) =
β1β2U(s) + β3D(s)
s+ β3
,
where the system output yp(t) (Yp(s)), the input u(t) (U(s)), and d(t) (D(s)) can
be observed. Hence, in our setting, the system transfer function is Gp(s,θ
∗
p) =
Yp(s)/U(s) and it is parameterized by β1, β2 and β3. In this case, θ
∗
p = (β1, β2,
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β3).
Next, we design a reference transfer function Wm(s). We take Wm(s) to be a
first-order LTI system driven by a reference signal r(t):
Wm(s) =
Ym(s)
R(s)
=
bm
s+ am
,
which is equivalent to
y˙m(t) =− amym(t) + bmr(t), or (3.5)
Ym(s) =
bm
s+ am
R(s),
for any bounded piecewise continuous signal r(t), where am > 0, bm 6= 0 are known.
We assume that am, bm, and r(t) are chosen so that ym(t) represents the desired output
signal. This reference system is capable of driving the PPT value to the desired level
with a short transition time, which is significant in our medical application.
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Figure 3·3: The effect of the MRC law derived for and applied to one
randomly selected patient.
Before introducing the MRC law, we start with two definitions and a theorem.
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Definition 1. A state xe is said to be an equilibrium state of the system x˙ = f(t,x),
x(t0) = x0, where x ∈ Rn, f : T × B(r)→ Rn, T = [t0,∞), B(r) = {x ∈ Rn | ‖x‖ <
r}, if f(t,xe) ≡ 0 ∀t ≥ t0. We assume that f is such that for every x0 ∈ B(r) and
every t0 ∈ [0,∞), the system possesses one and only one solution x(t; t0,x0).
Definition 2. A equilibrium state xe is exponentially stable if there exits an α > 0
and for every  > 0 there exists δ() > 0, such that ‖x(t; t0,x0) − xe‖ ≤ e−α(t−t0),
∀t ≥ t0 whenever ‖x0 − xe‖ < δ().
Theorem 3.3.1. If we choose am > 0, bm 6= 0, and r(t) = Cr (constant), the
reference model equilibrium state yme =
bmCr
am
is exponentially stable.
Proof. The solution to Eq. (3.5) is
ym(t) = Φ(t, t0)ym(t0) +
t∫
t0
Φ(t, τ)bmr(τ)dτ,
where Φ(t, τ) = e−am(t−τ) is the state transition function in this problem. Since
r(t) = Cr, which is a constant, the solution to (3.5) can be written as
ym(t; t0, ym(t0)) = e
−am(t−t0)
(
ym(t0)− bmCr
am
)
+
bmCr
am
. (3.6)
Equation (3.6) indicates that as ym(t; t0, ym(t0)) → bmCram which is a constant, as
t → ∞. In addition, using Definition 1, it can be easily verified that yme = bmCram
is the equilibrium state of our reference system. Furthermore, |ym(t; t0, ym(t0)) −
yme| = |e−am(t−t0)(ym(t0) − yme)| = |ym(t0) − yme|e−am(t−t0), ∀t ≥ t0. Therefore, by
Definition 2, it follows that the reference model equilibrium state yme is exponentially
stable.
We will now design a proper controller u(t) such that all signals in the closed-
loop system are bounded and the system output yp(t) tracks the reference model
output ym(t). The control law should be chosen so that the closed-loop plant transfer
function from the input r(t) to the output yp(t) is equal to the reference model transfer
function. Motivated by this, we propose the control law
C(s,θ∗e) = U(s) = −k∗1YP (s) + k∗2R(s)− k∗3D(s),
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or equivalently, in the time domain
u∗(t) = −k∗1yp(t) + k∗2r(t)− k∗3d(t), (3.7)
where k∗1, k
∗
2, k
∗
3 are controller coefficients chosen so that
Yp(s)
R(s)
=
bm
s+ am
=
Ym(s)
R(s)
. (3.8)
Eq. (3.8) is satisfied, if we select
k∗1 = −
1
β1β2
(β3 − am), k∗2 =
bm
β1β2
, k∗3 =
β3
β1β2
,
which yields
u(t) =
1
β1β2
(β3 − am)yp(t) + bm
β1β2
r(t)− β3
β1β2
d(t), (3.9)
provided of course that β1, β2, β3 6= 0, i.e., the system is controllable. Such a transfer
function matching guarantees that yp(t) = ym(t), ∀t ≥ t0, when yp(t0) = ym(t0), or
|yp(t)−ym(t)| → 0 exponentially fast when ym(t0) 6= yp(t0) for any bounded reference
signal r(t). We also note that, depending on the parameters of some patients, this
law may yield a negative control signal which can not be implemented in practice
(corresponds to “extraction of bivalirudin” from the patient). In such a case, we need
to set a lower threshold of zero for the control signal. The final MRC control signal
becomes max{0, u(t)} with u(t) defined as in (3.9).
We test the performance of the MRC on the data set we described in Section 3.2.2.
We only use the test set (1/3 of the total) for testing since the remaining training set
was used for model parameter identification. As mentioned before, d(t) (the linear
combination of physiological variables at time t) is a step-wise signal over time. By
applying the parameter identification method outlined in Section 3.2.2, we obtained
both population-wide parameter values and individual model parameter values.
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We tested the MRC control law on a subset of patients and the results were
qualitatively the same in each case. We report results from a randomly selected
patient who has identified model parameters and available input data. To that end,
we set the reference parameters as am = 10, bm = 700, r(t) = 1. Choosing these values
keeps the reference PTT value to be 70s, which is in the middle of the desirable range.
We note that these parameter values are simply an example and physicians have the
freedom of selecting alternative values depending on the stable value and response
time they wish to achieve.
The effect of the MRC law (3.9) on this randomly selected patient is shown in
Fig. 3·3. It can be seen that driven by inputs generated by the MRC law, the system
output quickly converges to the reference output (top figure). The tracking error
(e(t) = yp(t) − ym(t)) quickly converges to zero and remains at zero (second figure).
We also obtain the control signal which corresponds to the bivalirudin infusion rate
(third figure). The MRC control law we introduced is robust to the uncontrollable
signal d(t) (bottom figure). Although d(t) changes over time, the control signal can
adapt and drive the system to track the reference signal closely.
We next evaluate the performance of the MRC scheme on all patients in the
test set we described earlier. For performance evaluation, we use three performance
metrics. The first one is the Root Mean Square Error (RMSE), which for patient i is
defined as
RMSEi =
√√√√√ 1
Ti
t
Ti
i∑
t=t1i
(yip(ti)− yim(ti))2,
where t1i , . . . , t
Ti
i are the time instants at which we adapt the controller for patient
i. We define RMSE for the whole population of patients as the average per patient
RMSE, i.e., RMSE= 1
Nt
∑Nt
i=1 RMSEi, where Nt is the number of patients in the test
set. We also define σEi to be the standard deviation of the errors e
i(t) = yip(t)−yim(t),
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t = t1i , . . . , t
Ti
i , of patient i. Similarly, we define σE as the average standard deviation
of σEi’s, i.e., σE =
1
Nt
∑Nt
i=1 σEi.
To capture a notion of “relative” error, we also compute the Normalized Root
Mean Square Error (NRMSE) defined for each patient i as
NRMSEi =
√√√√√ 1
Ti
t
Ti
i∑
t=t1i
[(yip(ti)− yim(ti))/yim(ti)]2.
As with the RMSE, we define the population-wide NRMSE as the average of NRMSEi’s
over the patients. Similarly, we also define σNEi as the standard deviation of the nor-
malized tracking errors ei(t) = (yip(t) − yim(t))/yim(t) for patient i, and σNE as the
average of σNEi’s over the patients.
Furthermore, to illustrate the percentage of PTT outliers which are outside clini-
cally safe bounds, i.e., not in the interval [ym(t)− 10, ym(t) + 10] during the transient
and not in the interval [60s, 80s] in steady-state, the Risk Percentage (RP) for patient
i is defined as
RPi =
N riski
Ti
,
where N riski is the number of time instants t
1
i , . . . , t
Ti
i at which the PTT value of
patient i is outside the safe bounds. Then, RP is defined as the average of RPi’s over
patients. We note that this metric is from a clinical perspective the most important
in assessing the efficacy of our methods. Table 3.1 reports the performance of the
MRC law for the patients in the test set.
In summary, in the case that model parameters are known, the MRC law tracks
the reference signal quite well as demonstrated by the low RMSE and NRMSE. The
RP value is zero, which completely assures clinical safety. The corresponding standard
deviations for RMSE and NRMSE are small as well.
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Table 3.1: Performance of the Model Reference Control (test set).
Metric Value
RMSE 0.84
σE 0.82
NRMSE 1.20%
σNE 1.17%
RP 0%
3.3.2 Indirect Model Reference Adaptive Control (MRAC)
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Figure 3·4: The MRC law derived for one patient but applied to
another patient.
As we mentioned in the Introduction, there is significant patient variability in
the response to bivalirudin. We have already established in section 2.4, that adapting
model parameters to individual patients leads to improved performance. This suggests
that the model structure is largely accurate but model parameters of an individual
patient can deviate from population-wide parameter values.
To better assess the effect of this variability, we test the performance of the MRC
law derived using parameter values of a specific patient when applied to another
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Table 3.2: Performance of the Inaccurate Model Reference Control
(test set).
Metric Value
RMSE 9.93
σE 3.98
NRMSE 14.18%
σNE 5.68%
RP 61.60%
patient with different model parameters. Fig. 3·4 plots the MRC law performance for
such a case. The top figure shows that there exists a large gap between the reference
output signal and the system output signal. In addition, the system output is outside
the safe range.
We also tested the MRC law derived using parameter values of a specific patient
against all patients in the test set. Table 3.2 reports the results. We note that RMSE,
NRMSE, and RP are substantially higher (and clinically unacceptable) than those
in Table 3.1. The difference of course is due to the fact the results of Table 3.1
are obtained when using the MRC law with the correct model parameters for each
patient, whereas Table 3.2 results apply the MRC law with parameters of some patient
to another patient. The small values of σE and σNE in Table 3.2 indicate that
performance of the MRC law when used with the wrong parameters is consistently
poor. This situation should obviously be avoided because overdosing or underdosing
is very dangerous for the patients.
To address this important issue, we next develop a method that first estimates
the individual model parameters, and then adopts the MRC law we introduced using
a certainty equivalence principle (Ioannou and Kosmatopoulos, 2006). Such a control
scheme is called indirect Model Reference Adaptive Control (MRAC) law.
By adding and subtracting −amyp(t) to (3.4), we can obtain the State-Space Para-
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metric Model (SSPM):
y˙p(t) = −amyp(t) + (am − β3)yp(t) + β1β2u(t) + β3d(t). (3.10)
Based on (3.10), the series-parallel estimation model (Ioannou and Sun, 2012) is given
by:
˙̂yp(t) = −amŷp(t) + (am − β̂3(t))yp(t) + β̂1(t)β̂2(t)u(t) + β̂3(t)d(t), (3.11)
where ŷp(t) is an estimated value of yp(t), and β̂1(t), β̂2(t), β̂3(t) are estimates of the
system parameters β1, β2, and β3 at time t. Note that in (3.11), yp(t) is treated as
an input available for measurement. By using the certainty equivalence principle (cf.
(3.9)), we take the control scheme structure to be:
u(t) = −k1(t)yp(t) + k2(t)r(t)− k3(t)d(t), (3.12)
where
k1(t) =
am − β̂3(t)
β̂1(t)β̂2(t)
, k2(t) =
bm
β̂1(t)β̂2(t)
, k3(t) =
β̂3(t)
β̂1(t)β̂2(t)
.
In this problem, we will estimate the product of β1(t) and β2(t) instead of estimating
them separately. The model estimation error is e(t) = yp(t)− ŷp(t) which implies:
e˙(t) =y˙p(t)− ˙̂yp(t)
=− ame(t) + β˜3(t)(yp(t)− d(t))− β˜12(t)u(t), (3.13)
where
β˜3(t) = β̂3(t)− β3, β˜12(t) = β̂1(t)β̂2(t)− β1β2. (3.14)
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Figure 3·5: The performance of the indirect MRAC law.
We now choose a Lyapunov-like function
V (t) =
1
2
e(t)2 +
1
2γ1
β˜3(t)
2 +
1
2γ2
β˜12(t)
2, (3.15)
which, with γ1, γ2 > 0, is non-negative for all t. By taking the derivative on both
sides of (3.15) we obtain
V˙ (t) =e(t)e˙(t) +
1
γ1
β˜3(t)
˙˜β3(t) +
1
γ2
β˜12(t)
˙˜β12(t)
=− am(e(t))2 + β˜3(t)
[
e(t)(yp(t)− d(t)) + 1
γ1
˙˜β3(t)
]
+ β˜12(t)
[
1
γ2
˙˜β12(t)− e(t)u(t)
]
. (3.16)
Then, choosing
˙˜β3(t) = −γ1(yp(t)− d(t))e(t) and ˙˜β12(t) = γ2e(t)u(t)
leads to V˙ (t) = −ame(t)2 ≤ 0. In addition, since β1β2 and β3 are constants, (3.14)
implies ˙˜β3(t) =
˙̂
β3(t) and
˙˜β12(t) = d(β̂1(t)β̂2(t))/dt. It follows that we could estimate
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the model parameters by:
β̂3(t+ ∆t) = β̂3(t) +
˙̂
β3(t)∆t,
β̂12(t+ ∆t) = β̂12(t) +
d(β̂1(t)β̂2(t))
dt
∆t,
(3.17)
for small ∆t. Then, we can adapt the controller coefficients recursively and control
the system in real-time by using (cf. (3.12))
u∗(t) = −am − β̂3(t)
β̂12(t)
yp(t) +
bm
β̂12(t)
r(t)− β̂3(t)
β̂12(t)
d(t). (3.18)
Similarly, as we did earlier for the MRC law, we will use the control max{0, u∗(t)}
to avoid negative values.
Theorem 3.3.2. Under the control law (3.18), the tracking error converges to 0 as
t→∞.
Proof. By choosing such control law, V˙ (t) = −ame(t)2 ≤ 0, ∀t > t0. Since V (t) is
bounded from below and non-increasing, it converges to a constant. This implies that
−am
∫∞
t0
e2(t)dt = V (∞)− V (t0) is bounded, which in turn implies that e(t) → 0 as
t→∞ according to Barbalat’s lemma (Popov and Georgescu, 1973). It also follows
that ˙˜β3(t),
˙˜β12(t)→ 0 as t→∞.
One key flaw of the adaptive control law (3.18) is that the boundness of control
signal u(t) can not be established unless we show that k1(t), k2(t), k3(t) are all
bounded. However, such a control law may generate estimates of β1β2 arbitrarily
close or even equal to zero, which leads to the uncontrollability of the estimated
model and unboundness of u(t). To avoid this issue, we propose a modification to
the control law (3.18). One method is to modify the adaptive law for β̂12(t) so that
adaptation takes place in a subset of R which does not include the zero element. We
need to use the a priori knowledge of β1 ≥ βlb1 > 0 and β2 ≥ βlb2 > 0 to do the
projection:
˙˜β3(t) =− γ1(yp(t)− d(t))e(t),
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˙˜β12(t) =

γ2e(t)u(t), if |β˜12(t)| > βlb1 βlb2 ,
or |β˜12(t)| = βlb1 βlb2
and e(t)u(t)sgn(β˜12(t)) ≥ 0,
0, otherwise.
(3.19)
After modifying the adaptive control law, the time derivative of the Lyapunov function
becomes:
V˙ (t) =

−am(e(t))2, if |β˜12(t)| > βlb1 βlb2 ,
or |β˜12(t)| = βlb1 βlb2
and e(t)u(t)sgn(β˜12) ≥ 0,
−am(e(t))2
+β˜12(t)e(t)u(t), if |β˜12(t)| = βlb1 βlb2
and e(t)u(t)sgn(β˜12(t)) < 0.
Therefore, V˙ (t) ≤ −ame2(t) ≤ 0, ∀t ≥ t0.
Using a similar argument as before, it can be shown that by using this modified
parameter estimation law (3.19), the tracking error converges to zero driven by a
bounded control signal. Additionally, we have shown (cf. Thm. 3.3.1) that the ref-
erence output response is exponentially stable, and it follows that the system output
can be driven to the stable state exponentially fast.
We next test the indirect MRAC law using the patient data. The parameter values
of the reference model are the same as in Section 3.3.1. We choose the population-
wide parameter values β∗3 = 7.9× 10−4, and β∗1β∗2 = 4.22 as initial values of β̂3(t) and
β̂12(t), respectively. The MRAC adapts based on these estimates in real-time. We
also set γ1 = γ2 = 5× 10−4. The trajectory of the system under the indirect MRAC
is shown in Fig. 3·5.
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Fig. 3·5 indicates that the system output quickly converges to the reference output
and it remains within the desired range (top figure). The tracking error oscillates
around zero (middle figure), but it is not as smooth as in Fig. 3·3. This is due to
the fact that the indirect MRAC takes some time to estimate the system parameters
first and then adapts the controller coefficients. Similarly, we can also obtain the
bivalirudin infusion rate (bottom figure). Notice that although d(t) changes over
time, the control signal can drive the system to track the reference output signal
well. The performance of indirect MRAC for all patients in the test set is reported
in Table 3.3.
Table 3.3: Performance of the Indirect Model Reference Adaptive
Control (test set).
Metric Value
RMSE 5.52
σE 2.00
NRMSE 7.88%
σNE 2.86%
RP 2.30%
We note that in this case, the values of our three performance metrics are all higher
than those in the Table 3.1. This is again explained by the fact that adaptation of
the indirect MRAC law is not very fast due to the parameter estimation step. Yet,
RMSE, NRMSE and RP values are now significantly less than those in Table 3.2 and
they could be considered acceptable in a clinical setting.
3.3.3 Direct Model Reference Adaptive Control MRAC
In this section, we focus on designing the direct MRAC without estimating the model
parameters first. Because the individual model parameters are unknown, we can not
apply the MRC law directly. Based on the structure of MRC law, we propose an
48
0 2 4 6 8 10 12 14 16 18 20
0
20
40
60
80
si
gn
al
(s)
 
 
plant output
reference output
lower bound
upper bound
0 2 4 6 8 10 12 14 16 18 20
−10
−5
0
5
10
e
rr
o
r(s
)
 
 
error(plant−reference)
0 2 4 6 8 10 12 14 16 18 20
0
100
200
300
time(days)
co
n
tro
l s
ig
na
l(m
g/k
g/h
)
 
 
bival rate
Figure 3·6: The performance of direct MRAC law.
adaptive control law with similar structure:
u(t) = −k̂1(t)yp(t) + k̂2(t)r(t)− k̂3(t)d(t),
where k̂1(t), k̂2(t), and k̂3(t) are the estimates of MRC controller coefficients k
∗
1, k
∗
2,
and k∗3 at time t, respectively. We will devise a control law that estimates these
coefficients directly.
Consider the error derivative:
e˙(t) =y˙p(t)− y˙m(t)
=− ame(t) + β1β2[−k˜1(t)yp(t) + k˜2(t)r(t)− k˜3(t)d(t)],
where k˜i(t) = k̂i(t)− k∗i , i = 1, 2, 3. It follows that ˙̂ki(t) = ˙˜ki(t), i = 1, 2, 3.
To design the controller, consider the Lyapunov-like function:
V (t) =
e(t)2
2
+ β1β2
[
k˜1(t)
2
2γ1
+
k˜2(t)
2
2γ2
+
k˜3(t)
2
2γ3
]
.
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By taking the derivative, we obtain:
V˙ (t) = e˙(t)e(t) + β1β2
[
k˜1(t)
˙˜k1(t)
γ1
+
k˜2(t)
˙˜k2(t)
γ2
+
k˜3(t)
˙˜k3(t)
γ3
]
= −ame2(t) + β1β2
[
k˜1(t)
γ1
( ˙˜k1(t)− e(t)γ1yp(t))
+
k˜2(t)
γ2
( ˙˜k2(t) + e(t)γ2r(t)) +
k˜3(t)
γ3
( ˙˜k3(t)− e(t)γ3d(t))
]
,
where we have the a priori knowledge that β1β2 > 0.
Choosing
˙˜k1(t) =γ1e(t)yp(t),
˙˜k2(t) =− γ2e(t)r(t),
˙˜k3(t) =γ3e(t)d(t),
leads to V˙ (t) = −ame(t)2 ≤ 0. Furthermore, the controller coefficients can be adapted
by
k̂i(t+ ∆t) = k̂i(t) +
˙̂
ki(t)∆t, i = 1, 2, 3,
and our direct MRAC controller becomes
u(t) = −k̂1(t)yp(t) + k̂2(t)r(t)− k̂3(t)d(t). (3.20)
As with the previous two controllers, we will use max{0, u(t)} to avoid negative
controls.
We establish the following result; we omit the proof because it is similar to the
proof of Theorem 3.3.2.
Theorem 3.3.3. Under the control law (3.20), the tracking error converges to 0 as
t→∞.
We know that the reference model output is exponentially stable and the tracking
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error converges to zero as t increases, which establishes that the system output can
be driven to track the reference output well. To avoid overdosing and underdosing
risks that may occur in the time it takes the MRAC to converge to the appropriate
controller parameters, we can use as initial estimates of these coefficients the MRC
coefficients, namely k̂1(0) = 2.37, k̂2(0) = 165.75, and k̂3(0) = 1.87 × 10−4, obtained
from a system model parametrized with population-wide parameters.
We applied such a direct MRAC law to the same patient used for generating
Fig. 3·5. The result is shown in Fig. 3·6 (using γ1 = γ2 = γ3 = 0.001). We note that
driven by the direct MRAC law, the system output quickly converges to the reference
output. Although the system output oscillates around the reference signal, it remains
within the desired range (top figure). The tracking error also converges to zero (middle
figure). We also plot the bivalirudin infusion rate (bottom figure). Compared to the
indirect MRAC, the direct MRAC has similar performance on controlling the PTT.
However, the direct MRAC avoids parameter estimation and estimates controller
parameters directly.
Table 3.4: Performance of the Direct Model Reference Adaptive Con-
trol (test set).
Metric Value
RMSE 0.80
σE 0.80
NRMSE 1.15%
σNE 1.14%
RP 0.09%
Table 3.5 reports the performances of all three adaptive control laws, including
the direct MRAC for the patients in the test set. Compared to the results from the
indirect MRAC, the direct MRAC achieves lower values for all performance metrics,
i.e., RMSE, NRMSE, σE, σNE and RP. Notice the rather significant decrease of the
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Table 3.5: Performances of the three control laws (test set).
Metric MRC Indirect MRAC Direct MRAC
RMSE 0.84 5.52 0.80
σE 0.82 2.00 0.80
NRMSE 1.20% 7.88% 1.15%
σNE 1.17% 2.68% 1.14%
RP 0% 2.30% 0.09%
RP value, which, as we argued, is clinically a top priority. This table validates the fact
that the direct MRAC is a more efficient and safer control scheme than the indirect
MRAC.
3.4 Conclusions
Based on a specific dynamic system model of bivalirudin acting in cardiac surgical
patients, we developed two methods for synthesizing a controller to regulate the bi-
valirudin infusion rate and induce a PTT within a desirable range. The first method
assumes that the model parameters are available and develops a control law that
tracks a physician specified reference output signal. Our second method considers
patients for which past clinical records are sparse and accurate model parameters are
not readily available. It develops an indirect control scheme (indirect MRAC) that
first estimates the model parameters and then adapts the corresponding controller
based on these estimates. Alternatively, a direct control scheme (direct MRAC) that
adapts the controller without estimating the model parameters first is also developed.
Testing of these schemes against actual patient data from a hospital, shows that the
direct MRAC is more efficient than the indirect version.
The methods we developed can be seen as key steps towards automation of dosage
decisions in a hospital setting, which can help eliminate errors and neutralize the
inexperience of residents who are currently responsible for these decisions.
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Chapter 4
Learning Cellular Objectives from Fluxes
by Inverse Optimization
4.1 Introduction
In this chapter, we switch our scope from the human to the cellular metabolism.
Specifically, we focus on the genome-scale flux balance models of metabolism. These
models provide testable predictions of all metabolic rates in an organism, by assuming
that the cell is optimizing a metabolic goal known as the objective function. In prac-
tice, however, reaction fluxes of the cells under specific growth conditions are available
to be measured with 13C technology (Zamboni et al., 2009), but the primal goals of
cells are not necessarily known. Understanding the metabolic network structure can
elucidate the cellular metabolic control mechanisms and infer important information
regarding an organism’s evolution.
A metabolic network is used to describe the process of thousands of enzymatic
reactions used to convert nutrients into metabolites and energy. Organisms have
different optimal performances (e.g., maximizing growth rate, ATP generation) under
a range of growth conditions (Edwards et al., 2001; Sauer et al., 1998; Papoutsakis,
1984). Flux Balance Analysis (FBA) (Kauffman et al., 2003) has emerged as one of
the most important methodologies to analyze the metabolic network in steady-state.
FBA formulates the problem of predicting the metabolic reaction fluxes as a linear
programming problem. Let S ∈ Rm×n denote the stoichiometric matrix (expressing
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mass balance) where m is the number of metabolites and n the number of metabolic
fluxes, x ∈ Rn the vector of metabolic fluxes (internal and external), and vlb, vub
lower and upper bounds on the metabolic fluxes implied by the composition of the
growth medium. External fluxes represent the transfer rates between metabolites
which exist inside and outside of the cell. Internal fluxes represent the reactions rates
among metabolites inside of the cell. The FBA problem is formulated as:
Zopt = max
x
c′x (4.1)
s.t. Sx = 0,
vlb ≤ x ≤ vub,
where 0 is the vector of all zeroes, c the vector of coefficients expressing the cellular
objective (e.g., biomass), and we use Zopt to denote the optimal objective value. In
addition, we will use F to denote the feasible set. Fig. 4·1 illustrates the polyhedral
feasible set of the FBA problem and possible scenarios on where the optimal metabolic
flux distribution, say x∗, may lie.
In most applications of FBA, maximizing the biomass growth rate is assumed to
be the unique objective function. Yet, our knowledge of the optimal performances
(objective functions) that govern the fluxes distributions is quite limited and alter-
natives to biomass have been proposed. In (Schuetz et al., 2012), it is suggested that
other than maximizing the biomass growth rate, cells also try to minimize the effort
to adjust to a new environment. Mathematically, this performance can be formulated
as a quadratic objective function. In (Harcombe et al., 2013), comparing ancestral
and evolved strains of E. coli indicated that evolved strains migrate away from pre-
dicted optimal fluxes obtained by FBA with a biomass growth rate as an objective
function. Experimentally, intra-cellular fluxes are available to be measured by the
13C-based flux analysis technique. In this chapter, we seek to infer the right objective
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objective 1
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Figure 4·1: The feasible set of the FBA problem is a polyhedron –
the intersection of points satisfying the linear constraints of (4.1). xj,
j = 1, . . . , 4, denote extreme points of the feasible set. Depending
on the objective function coefficient c, one of these extreme points is
optimal. In some cases, a particular c can lead to multiple extreme
points being optimal (purple case), in which case the whole edge/facet
containing them is optimal. Notice, that for each optimal extreme point
there are many c’s that could have led to its optimality. These “valid”
c’s belong to a cone (cf. the four colored cones drawn).
function of a cell based on available measurements of internal and external fluxes
under a certain growth condition.
Towards the same goal, some FBA-based methods have been proposed. (Burgard
and Maranas, 2003) formulated the objective inference problem as a least squares
problem with a bi-linear feasible region. This is a non-convex formulation which does
not guarantee global optimality. In (Gianchandani et al., 2008), a bi-level nonlinear
optimization formulation was proposed. In this nonlinear optimization, the computa-
tion cost is substantial when the size of problem becomes large, and global optimality
55
cannot be guaranteed either. In (Knorr et al., 2007), a Bayesian-based selection of
metabolic objective functions was proposed. This is a probabilistic approach, which
is unable to yield any deterministic solution and biological insights. In this chap-
ter, leveraging a more general framework developed in (Bertsimas et al., 2013), we
develop a novel convex optimization-based framework called InvFBA to infer the cel-
lular objective function from the experimentally measured fluxes. In our InvFBA
formulation, the linearity of constraints and the convexity of the objective function
provide global optimality guarantees and an efficient algorithm (polynomial time).
We provide both the theoretical underpinnings and the biological insight behind the
InvFBA approach. In essence, our approach characterizes a family of objective func-
tions consistent with the given measurements. To recover a single and biologically
meaningful objective function we propose a proper regularization technique.
This chapter is organized as follows. In Section 4.2, based on the FBA framework,
we develop three invFBA methods to infer linear, quadratic and non-parametric cel-
lular objective functions respectively. We also provide a rigorous proof and geometric
understanding of InvFBA methods. In Section 4.3, we test our invFBA methods on
different data sets and assess their performances from different aspects.
4.2 Inverse Process of FBA
Solving (4.1) in practice, often leads to multiple optimal solutions. Thus, to select a
unique optimal solution from the optimal solution set, a second optimization problem
is used. In particular, one minimizes the l1-norm of the metabolic flux vector subject
to the constraints of (4.1) and one constraint that guarantees that the same objective
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value is achieved (Kauffman et al., 2003). The formulation is:
minx
∑n
i=1 |xi|
s.t. c′x = Zopt,
Sx = 0,
vlb ≤ x ≤ vub.
(4.2)
The optimal solution x∗ to problem (4.2) is the theoretical prediction of the flux
distribution inside the cell. FBA has been widely used to predict the flux distributions
of cells under different growth conditions.
We now introduce an inverse procedure of FBA – InvFBA. As explained earlier,
the main motivation for invFBA is that the cellular objective, which is often assumed
to be biomass maximization, may not always be valid especially at “transition” times
when the composition of the growth medium changes. Given that experimentally
measured metabolic flux distributions become more accessible, it becomes interesting
to leverage that information to infer the cellular objective. We will discuss three
different forms of the objective functions: linear, quadratic, and non-parametric.
4.2.1 Inverse FBA with Linear Objective Function
We assume that the FBA objective function is of the form Z(x) = c′x but c is un-
known. We have, however, access to N measured metabolic flux distribution vectors
(xi, i = 1, . . . , N). Due to potential measurement noise or other forms of error, xi
are feasible solutions of (4.1) but not necessarily optimal. We define a notion of
approximate optimality.
Definition 4.2.1. The feasible solution xi ∈ F is an i-approximate optimal solution
to FBA problem (4.1) if
c′x∗ − c′xi = i, ∀x ∈ F , (4.3)
where x∗ is an optimal solution of problem (4.1).
In the above definition, i ≥ 0 denotes the suboptimality gap. The next theorem
characterizes the space of objective vectors c corresponding to xi.
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Theorem 4.2.1. Suppose the FBA problem (4.1) is feasible. Then, the solution xi
is an i-approximate optimal solution to problem (4.1) if and only if there exist p
i,qi1
and qi2 satisfying
pi
′
S− qi′1 + qi
′
2 =c
′,
qi
′
2vub − qi
′
1vlb − i =c′xi, (4.4)
q1,q2 ≥0.
Proof. First suppose that xi is an i−approximate optimal solution. Then, from Eq.
(4.3), it follows
c′xi + i = max
x∈F
c′x, ∀x ∈ F .
The right hand side is the optimal value of a linear programming problem over x.
Since F 6= ∅, strong duality holds, which implies that there exists dual variables pi, qi1
and qi2 corresponding to the constraints Sx = 0, x ≥ vlb, and x ≤ vub, respectively,
and attain the optimum in the dual problem of (4.1), which is
minp,q1,q2 q
′
2vub − q′1vlb
s.t. p′S− q′1 + q′2 = c′,
q1,q2 ≥ 0.
(4.5)
Because of the strong duality, we have maxx∈F c′x equals the optimal value of (4.5).
By substituting this duality constraint and rearranging all equations above we es-
tablish the result. The reverse direction of the proof is analogous and easy to be
completed.
Notice that the equations in Thm 4.2.1 describe a set of c’s that lead to the near-
optimality of xi. In particular, they describe a cone C, i.e., a set that contains all non-
negative multiples of its elements. This conclusion is quite intuitive since it suffices to
determine the objective coefficient vector up to a non-negative multiplicative constant.
It is now clear that FBA does not lead to unique inference of the cellular objective
from measured fluxes.
Collecting the constraints in (4.4) for all measurements i = 1, . . . , N and minimiz-
ing the total suboptimality gap of the measured flux distribution vectors we obtain
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the optimization problem:
mini,pi,qi1,qi2,c
∑N
i=1 i
s.t. pi
′
S− qi′1 + qi′2 = c′, ∀i,
qi
′
2vub − qi′1vlb − i = c′xi, ∀i,
q1,q2 ≥ 0, ∀i,
i ≥ 0, ∀i.
(4.6)
The problem above has the trivial solution c = 0 and this is reasonable given
our observation that we can only determine the objective coefficient vector up to a
non-negative multiplicative constant. It follows, that we need to introduce some form
of regularization to restrict c to non-trivial choices.
c1
c2
c3
c4
c23
c34
c41
c12
x1
x2
x3
x4
c1c4
c4
c3
c2
c3
c12
c23
c34
c41
c2
c1x
d3 d2
d1
d4
Figure 4·2: (Left): The union of these cones is all of Rn (n = 2, in the
figure). If we use an `2-norm regularization in the invFBA formulation,
“valid” c’s lie on the surface of the unit ball in Rn. (Right): Illustra-
tion of the geometric intuition behind `2-regularized FBA. The FBA
feasible polyhedron can be partitioned using bisector lines. In this 2-
dimensional example, the polyhedron is partitioned by 4 bisectors into
4 (colored) polytopes. For example, if the observed flux distribution
x lies in the yellow polytope then c1 is the corresponding objective
function. If, however, the observed flux distribution lies in the bisector
between the blue and the yellow region, invFBA will yield either c1 or
c4.
One of the possible regularizations is to add to the formulation in (4.6) the `2-
norm equality constraint ‖c‖2 = 1. In this case, the objective function coefficient
vector c lies on the surface of the unit ball in Rn (cf. Fig. 4·2). To gain more
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geometric insight into the proposed `2-regularized invFBA, consider the case of a
single measured metabolic flux vector, say x (i.e., N = 1). Solving problem (4.6)
amounts to minimizing c′(xj − x) over all c and all extreme points xj of the FBA
polyhedron (feasible set of (4.1)). We have
min
j
c′(xj − x) = min
j
‖c‖‖xj − x‖ cosα, (4.7)
where α is the angle between c and xj−x and ‖xj−x‖ cosα is the projection of xj−x
onto c. Thus, and since ‖c‖ = 1, minimizing (4.7) over c is equivalent to projecting
x on all facets of the FBA polyhedron and selecting the c that is perpendicular to
the closest facet. As an example, in Fig. 4·2 (right), we compare the distances dj,
j = 1 · · · , 4, between x and the four facets, which yields d1 as the minimum and sets
the corresponding optimal objective coefficient vector to c1.
We have already discussed that FBA is used in practice with an additional sparsity-
inducing `1-norm regularization (cf. (4.2)). This motivates the use of a similar reg-
ularization in the context of invFBA. An `1-norm is appealing because one would
essentially be looking for the sparse c vectors rendering a given set of measured
metabolic flux distributions FBA-optimal. An `1-norm constraint can also be seen
as a relaxation of the combinatorial problem that minimizes the number of nonzero
elements of c in (4.6). To make the objective coefficient vector c non-zero and bio-
logically interpretable, we will add a normalization constraint and look for c’s such
that
∑n
j=1 cj = 1. This leads to the formulation:
ZIopt = mini,pi,qi1,qi2,c
∑N
i=1 i
s.t.
∑n
j=1 cj = 1,
pi
′
S− qi′1 + qi′2 = c′, ∀i,
qi
′
2vub − qi′1vlb − i = c′xi, ∀i,
q1,q2 ≥ 0, ∀i,
i ≥ 0, ∀i,
(4.8)
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where ZIopt denotes the optimal value.
Again motivated by the 2nd step in (4.2) of FBA’s application in practice, we also
propose a subsequent step whose purpose is to minimize the `1-norm of c = (c1, . . . , cn)
vectors that solve (4.8):
mini,pi,qi1,qi2,c
∑n
i=1 |ci|
s.t.
∑N
i=1 i = Z
I
opt,∑n
j=1 cj = 1
pi
′
S− qi′1 + qi′2 = c′, ∀i,
qi
′
2vub − qi′1vlb − i = c′xi, ∀i,
q1,q2 ≥ 0, ∀i,
i ≥ 0, ∀i.
(4.9)
Part of the optimal solution of (4.9) is a sparse c vector that renders the given
set of measured metabolic flux distributions x1, . . . ,xN near-optimal in the FBA op-
timization (4.1). One can then interpret non-zero elements of c as corresponding to
important metabolic fluxes that are critical in the FBA optimization context and
provide a minimal description of the cellular objective function. In the sequel, when
we refer to the invFBA algorithm we will mean the 2-step procedure of solving prob-
lems (4.8) and (4.9). Due to the `1 regularization and the fact that several measured
metabolic flux vectors are used, the c resulting from invFBA may not be perpendic-
ular to one of the hyperplanes defining the FBA polytope; it can in fact be interior
to the cone C containing all valid c’s.
Problems (4.9) is a linear programming problem minimizing the `1 norm of the
vector c. It can be viewed as a convex relaxation of a problem with identical con-
straints, which minimizes the `0 norm of c (i.e., the number of non-zero elements in
c). To pursue more sparse objective functions, an integer programming problem is
introduced to minimize the `0-norm of c. This problem is formulated as:
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mini,pi,qi1,qi2,c,z
∑n
j=1 zj
s.t.
∑N
i=1 i = Z
I
opt,∑n
j=1 cj = 1
pi
′
S− qi′1 + qi′2 = c′, ∀i,
qi
′
2vub − qi′1vlb − i = c′xi, ∀i,
zj ≥ |cj |L , zj ∈ {0, 1}, ∀j,
q1,q2 ≥ 0, ∀i,
i ≥ 0, ∀i.
(4.10)
In (4.10), the binary variable zj is the indicator of whether cj is nonzero (then zj = 1)
or not (then, zj = 0). The constant L is a large number that together with the
integrality constraint zj ∈ {0, 1} forces zj to be 1 when cj is nonzero. Formulation
(4.10) is an integer programming problem and formulation (4.9) is a convex relax-
ation of (4.10). Of course, it is much more computationally expensive to solve (4.10)
compared to solving (4.9). We can, however, use the solution of (4.9) as a feasible
solution for (4.10), which can substantially speed up the solution time of (4.10) (using
the value of the (4.9) solution in a branch-and-bound algorithm for (4.10)).
An important observation is that both problems (4.8) and (4.9) that comprise our
invFBA algorithm are linear programming problems. This is important because a
global optimal solution is guaranteed (as opposed to earlier approaches as in (Burgard
and Maranas, 2003) where one deals with a non-convex problem). Moreover, very
efficient polynomial-time algorithms exist for solving such problems. It is interesting
that the complexity of the invFBA algorithm is exactly the same as that of FBA
– both are linear programming problems. This is not in general true for inverse
optimization problems (Bertsimas et al., 2013). An alternative LASSO-like invFBA
method is introduced in Appendix A.
To illustrate the use of the invFBA algorithm (4.8) and (4.9), we apply it to
a simple metabolic network shown in Fig. 4·3 (Left). The stoichiometric matrix is
S = [1, 2,−1] and we impose the constraint x3 ≤ 2. Thus, the FBA polyhedron
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Figure 4·3: (Left):A simple simulated metabolic network model with
a single metabolite A and three reactions. (Right): We plot the FBA
polyhedron on the x1–x2 plane. The red dot indicated a given metabolic
flux distribution. The invFBA algorithm yields c = (1/3, 2/3).
is {x | Sx = 0,x ≥ 0, x3 ≤ 2}. We eliminate x3 and plot in Fig. 4·3 (Right) the
polyhedron in the x1–x2 plane. The red dot shown in the figure identifies a given
metabolic flux distribution. The invFBA algorithm applied by using this point as the
measured flux vector yields c = (1/3, 2/3) which is the vector perpendicular to the
closest hyperplane. We note that if instead we seek the closest extreme point of the
FBA polytope to the red dot (as in (Burgard and Maranas, 2003; Gianchandani et al.,
2008)) then we would obtain the extreme point (x1, x2) = (0, 0) and a c that renders
this point optimal (i.e., a c in the green cone shown in the figure). It is clear from
the figure that such a cellular objective coefficient may not be the most appropriate.
4.2.2 Linear Objective Variability Analysis
To analyze the variability of each element in the objective function within the optimal
solution space, we developed a method called Objective Variability Analysis (OVA).
OVA is a heuristic optimization method used to compute the upper and lower bound
of the elements in the objective function. The first step of OVA is to solve the linear
optimization problem given in problem (4.9).
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By solving this problem, we can obtain an optimal solution for c and the optimal
objective value
∑N
i=1 i = Z
I
opt. Let < be the set of reaction indices which are impor-
tant in the FBA problem. To find the possible range for each cr, r ∈ <, we solve
(4.11)
mini,pi,qi1,qi2,c cr + |c|
s.t.
∑N
i=1 i = Z
I
opt,∑n
j=1 cj = 1
pi
′
S− qi′1 + qi′2 = c′, ∀i,
qi
′
2vub − qi′1vlb − i = c′xi, ∀i,
q1,q2 ≥ 0, ∀i,
i ≥ 0, ∀i,
(4.11)
and an identical problem with the only difference being that we maximize cr − |c|
(instead of minimizing) so as to find the largest possible value of cr and maintain a
small `1 norm of c. Solving these problems yields upper and lower bounds on each
elements in the objective function.
To apply OVA in practice, some extra constraints on c should be added to (4.11).
Consider reactions represented in the flux vectors xi which have a flux equal to zero
for all i. For these reactions, the corresponding elements cj in c can take arbitrary
feasible values because of the term c′xi in (4.11). For this reason, it is meaningless
to run OVA on these cj. To that end, we set cj = 0 for all those indices. In the
later case study involving simulated E. coli data, since the flux distributions are very
sparse, we applied this technique and focused on the non-trivial reactions only.
4.2.3 Inverse FBA with Quadratic Objective Function
As we have discussed in the Introduction, non-linear objectives have been proposed for
FBA, e.g., (Schuetz et al., 2012) which argued for a trade-off between optimality under
current growth conditions and minimal adjustment to past recent growth conditions.
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This reasoning motivates the following quadratic-FBA problem:
min c′x + β||x− xˆ||2
s.t. Sx = 0,
vlb ≤ x ≤ vub,
(4.12)
where β is some tunable and non-negative constant and xˆ the previously observed flux
distribution. We use function Z(x) = βx′x + (c− 2βxˆ)′x to represent the quadratic
objective function (ignoring a constant). A solution x∗ is optimal in problem (4.12)
if and only if it satisfies the optimality conditions
∇Z(x∗)′(x− x∗) ≥ 0, ∀x ∈ F . (4.13)
Similar to Definition 4.2.1, we provide a notion of approximate optimality.
Definition 4.2.2. The feasible solution xi ∈ F is an i-approximate optimal solution
to FBA problem (4.12) if
∇Z(xi)′(x− xi) ≥ −i, ∀x ∈ F . (4.14)
The following theorem characterizes the feasible space of unknown parameters c
and β corresponding to xi.
Theorem 4.2.2. Suppose F is non-empty. Then, the solution xi is an i-optimal
solution to problem (4.12) if and only if there exist pi, qi1, and q
i
2 satisfying
[c′ + 2β(xi − xˆ)′]xi − i ≤ qi′1vlb − qi′2vub,
S′pi + qi1 − qi2 = c + 2β(xi − xˆ),
qi1,q
i
2 ≥ 0.
(4.15)
Proof. First suppose that xi is an i-approximate optimal solution to (4.12). Then
from equation (4.13), that we have
∇Z(xi)′(x− xi) ≥ −i, ∀x ∈ F ,
which is equivalent to
∇Z(xi)′xi − i ≤ min
x∈F
∇Z(xi)′x.
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The right hand side is the optimal value of a linear programming problem whose dual
is
max
pi,qi1,q
i
2
qi
′
1vlb − qi′2vub
s.t. c + 2β(xi − xˆ) = S′pi + qi1 − qi2,
qi1,q
i
2 ≥ 0,
(4.16)
where pi, qi1 and q
i
2 are dual variables. Since F 6= ∅, strong duality holds which
implies that minx∈F ∇Z(xi)′x is equal to the optimal value of (4.16). This proves the
result. The reverse direction of the proof is analogous and easy to be completed.
Given Thm. 4.2.2 we formulate the inverse optimization problem as
min
pi,qi1,i,q
i
2,c,β
∑N
i=1 i + λ
∑n
j=1 |cj|
s.t. S′pi + qi1 − qi2 = c + 2β(xi − xˆ), ∀i,
[c′ + 2β(xi − xˆ)′]xi − i ≤ qi′1vlb − qi′2vub, ∀i,
qi1,q
i
2 ≥ 0, ∀i, β ≥ 0,∑n
j=1 cj = −1.
(4.17)
Similar to problem (A.1), we have again added the regularization term λ
∑n
j=1 |cj| to
induce a sparse vector c. Notice that (4.17) is a linear programming problem.
4.2.4 Inverse FBA with Non-parametric Objective Function
In practice, the activities of cells can be extremely complicated. Even though linear
or quadratic objective functions are able to describe these activities in most cases, we
next attempt to explore more general forms of objective functions that can improve
FBA modeling. To that end, we leverage ideas from machine learning and use kernel
methods to infer non-parametric forms of the objective function. As before, we will
use Z(x) to denote the convex objective and consider an FBA-like problem of
min
x∈F
Z(x). (4.18)
Kernel methods are commonly used for feature extraction, often in the context of
support vector machines or principal components analysis. A more thorough treat-
66
ment of kernel methods can be found in (Evgeniou et al., 2000). Consider the FBA
convex objective function Z(x) and let z(x) = ∇Z(x) = (z1(x), . . . , zn(x)). We
can let each zi ∈ H, i = 1, . . . , n, where H is a Reproducing Kernel Hilbert Space
(RKHS) (Hastie et al., 2009) with an associated positive semi-definite kernel func-
tion k : F × F → R. Different choices for the kernel are possible including linear,
polynomial, or a radial basis function.
According to the representer Theorem (Scho¨lkopf et al., 2001), scalar func-
tions f ∈ H can be written as linear combinations of kernel functions as f(x) =∑N
i=1 αik(xi,x). Let g another element of H, written as g(x) =
∑N
j=1 βjk(xj,x).
Then we can define an inner product over H as f, g ∈ H such that
〈f, g〉H =
N∑
i=1
N∑
j=1
αiβjk(xi,xj), (4.19)
and a norm by ||f ||H =
√〈f, f〉H. The norm ||f ||H is a measure of the “smoothness”
of the function f(·). Thus, functions with small norm are “smooth,” meaning that
they do not change rapidly in a small neighborhood of their argument.
As in earlier subsections, assume now we have access to N measured flux vectors
xi, i = 1, . . . , N . Each xi is an i-approximate optimal solution to the FBA problem
with objective function Z(x), where the notion of approximate optimality is the same
as in Definition 4.2.2. We can represent each partial derivative zi(x) of Z(x) as an
element ofH and express it as a linear combination of kernel functions as in zi(x;αi) =∑N
j=1 αi,jk(xj,x) for some appropriate coefficient vector αi = (αi,1, . . . , αi,N). Note
that z(xi;α) = αKei where α ∈ Rn×N is the matrix whose rows are the αi’s,
K = (k(xj,xi))
N
i,j=1 and ei is the ith unit vector.
The following theorem characterizes the set of objective function gradients that
are consistent with our measurements.
Theorem 4.2.3. Suppose F is non-empty. Then, the solution xi is an i-optimal
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solution to problem (4.18) if and only if there exist α, pi, qi1, and q
i
2 satisfying
(αKei)
′xi − i ≤ qi′1vlb − qi′2vub,
αKei = S
′pi + qi1 − qi2,
qi1,q
i
2 ≥ 0.
(4.20)
Proof. The proof is similar to that of Theorem 4.2.2. The only difference is that
z(xi;α) = αKei.
Biologically, we rarely expect cellular objectives to change rapidly within a small
time interval. Therefore, the smoothness of the objective function is a reasonable
assumption. We want, therefore, to find the objective function which leads to a small
suboptimality gap and a small norm. This leads to the following formulation:
min{zi∈H,i≥0, ∀i}
∑N
i=1 i + λ
∑n
i=1 ||zi||2H, (4.21)
where λ > 0 a tunable constant used to trade-off between the minimal optimality gap
and the smoothness of the objective function. Since zj(xi;α) = e
′
jαKei, it follows
that ||zj||2H = e′jαKα′ej. This yields the problem:
mini,pi,qi1,qi2,α
∑N
i=1 i + λ
∑n
j=1 e
′
jαKα
′
ej
s.t. αKei = S
′pi + qi1 − qi2, ∀i,
(αKei)
′xi − i ≤ qi′1vlb − qi′2vub, ∀i,
qi1,q
i
2 ≥ 0, ∀i,
i ≥ 0, ∀i,∑n
j=1
∑N
i=1 αj,i = 1,
(4.22)
where the last constraint is introduced for normalization purposes. By solving prob-
lem (4.22), we can obtain an optimal α∗ giving rise to a gradient function z(x;α∗).
Objective functions with the same gradient have the same optimal solution(s) for
the forward FBA problem. It can be easily seen that problem (4.22) is a quadratic
programming problem which guarantees tractability and global optimality.
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4.3 Numerical Examples
In this section, we will present several numerical examples to illustrate the perfor-
mance of our invFBA approaches from different aspects.
4.3.1 Inference of Linear Objective Functions in Simulated E. coli Fluxes
The objective function in FBA (Fig. 4·4) is encoded by a vector c, whose elements
represent the extent to which individual fluxes tend to be maximized or minimized
in the resource allocation problem that the cell tries to solve. Mathematically, the
linear combination of fluxes being maximized or minimized is expressed in the form∑n
j=1 cjxj, where n is the total number of reactions in the model. The problem
addressed by invFBA is to infer, from measurements of the fluxes under a given
condition, the vector c that best represents its objective. Most FBA calculations
include only one nonzero element in c, corresponding to the biomass production flux.
In our invFBA approach, we want to assume that more complex c vectors may better
capture the objective function implied by experimentally measured fluxes.
Before applying invFBA to experimental measurements of a cell’s metabolism
whose underlying objective is unknown, we first tested invFBA on in silico fluxes
simulated by FBA with a known objective. Using the iJO1366 metabolic model for
E. coli (Orth et al., 2011), we simulated growth in a standard minimal medium under
three different carbon source limitations: glucose, succinate, and glycerol. In all cases,
the objective function was chosen such that FBA maximizes the biomass reaction flux.
We next used the output flux vectors predicted by FBA (which we will refer to as
the “observed fluxes”) as an input to invFBA. The invFBA algorithm tries to infer
possible objective functions that could yield the observed fluxes as solutions in FBA.
Our standard formulation of invFBA works in two steps: the first step identifies a set
of objective functions compatible with the observed fluxes; the second step narrows
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Figure 4·4: This diagram illustrates concisely the flow of information
for invFBA calculations in this work. The right part of the figure dis-
plays schematic representations of the set of metabolic fluxes. Each
flux vector can also be visualized on a metabolic chart (right-most part
of the figure), where gray arrows of different thicknesses indicate differ-
ent intensities of reaction fluxes throughout a network. The left part
of the figure displays instead the space of metabolic objectives. Coef-
ficients of the objective function can also be visualized on a metabolic
chart (left-most part of the figure), with red arrows representing non-
zero components of the objective. (A) FBA uses a given objective
function (here cgrowth) to predict a set of fluxes (X
Opt), or multiple
equivalent sets of fluxes (not shown). From one FBA solution one can
use InvFBA to infer possible objective functions. The solution is not
necessarily unique, though the space of possible solutions can be rigor-
ously characterized, and contains the original objective function. (B)
InvFBA can be applied to multiple (noisy) experimental measurements
of fluxes, leading, as in the test case of panel A, to a space of possible
objective functions.
down this set to a putative sparse objective, with a minimal `1 norm. The third step
is alternatively used to find the sparsest objective (which has a minimal number of
nonzero elements in the objective function) if needed.
70
Table 4.1: InvFBA results from `1 and `0 norm regularization of sim-
ulated E. coli data under different growth conditions.
Growth condition `1 normregularization
`0 norm
regularization
Glucose
minimal medium
# of non-zero in c
elements 15 1
maximal reaction
name biomass growth biomass growth
The maximal
value 0.7676 1
Succinate
minimal medium
# of non-zero in c
elements 1 1
maximal reaction
name biomass growth biomass growth
The maximal
value 1 1
Glycerol
minimal medium
# of non-zero in c
elements 3 1
maximal reaction
name biomass growth biomass growth
The maximal
value 0.7065 1
Upon applying invFBA to the FBA-generated observed fluxes, we found that the
algorithm correctly recovered maximization of the biomass flux in all three conditions
(inferred coefficients are shown in Table 4.1). One immediate question is whether this
solution is unique. In order to explore the spectrum of possible equivalent invFBA
solutions, we extended to invFBA the method of flux variability analysis often used
in classical FBA calculations (Orth et al., 2010). In this case, we wanted to charac-
terize the possible range for each possible element in the objective function vector c.
The OVA we introduced before determines the full range of values each coefficient of
the objective function can assume while being consistent with optimality. By running
OVA to these test cases, we found that while invFBA yielded maximization of biomass
as a solution under all conditions, alternative objective functions were equally com-
patible with the observed fluxes under the different conditions. For instance, under
succinate-limited medium, an equivalent objective function is the maximization of
succinate uptake. While surprising at first, this result is intuitive considering that,
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to maximize growth, the cell needs to maximize uptake of its limiting nutrient. This
simple example already points out an important aspect of FBA and its inverse prob-
lem, as rigorously addressed by invFBA: while the inverse algorithm rules out a large
subset of objectives whose optimization could not possibly lead to the observed fluxes,
different c vectors may still, when used in FBA, yield the same observed fluxes. Note
that if two such equivalent objectives were used in the forward FBA problem, it is
not guaranteed they will produce the same fluxes, due to the existence of alternative
optimal solutions in FBA itself. Yet, any c inferred by invFBA will produce a flux
distribution lying on the facet of the FBA polyhedron, which contains all optimal
flux distributions. While the above analysis was focused on testing the capacity of in-
vFBA to recover growth maximization as the underlying objective, one may wonder
whether the algorithm could similarly recover alternative objectives. Towards this
goal, we generated FBA-predicted fluxes using maximization of ATP synthase flux
and minimization of glucose uptake for a fixed growth rate as alternative objectives.
As shown in Tables 4.2 and 4.3, the sparse invFBA algorithm consistently recovered
the correct objective function.
4.3.2 Recovering Objectives and Fluxes From Noisy Data
Unlike fluxes predicted by FBA simulations, experimentally observed fluxes will likely
contain some noise that may mask the compatibility with different optimality criteria.
For example, while any FBA flux vector predicted through the maximization of the
biomass flux will have precisely the maximal possible growth flux value, experimen-
tally measured fluxes, even if close to a growth optimum, will likely fall within an
area around it. In order to simulate this process, and test invFBA under noisy flux
measurements, we implemented our inverse algorithm under increasing levels of noise,
and tested our capacity to recover the correct objective. In particular, we wanted to
add noise to the optimal solution of FBA while keeping noisy fluxes in the feasible so-
72
Table 4.2: InvFBA results from `1 and `0 regularization of simulated
E. coli data under different growth conditions (Maximization of ATP
synthase).
Growth condition `1 normregularization
`0 norm
regularization
Glucose
minimal medium
# of non-zero
elements in c 3 1
Reaction of
maximal coefficient ATP synthase ATP synthase
The maximal
value 0.8333 1
Succinate
minimal medium
# of non-zero
elements in c 1 1
Reaction of
maximal coefficient ATP synthase ATP synthase
The maximal
value 1 1
Glycerol
minimal medium
# of non-zero
elements in c 2 1
Reaction of
maximal coefficient ATP synthase ATP synthase
The maximal
value 0.8333 1
Table 4.3: InvFBA results from `1 and `0 regularization of simulated
E. coli data under glucose minimal medium (Minimization of glucose
uptake).
Growth condition `1 normregularization
`0 norm
regularization
Glucose
minimal medium
# of non-zero
elements in c 1 1
Reaction of
maximal coefficient D-Glucose exchange D-Glucose exchange
The maximal
value 1 1
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lution space (i.e., such that all reactions are in steady state and mass-balanced). This
can be achieved by running an additional FBA-like optimization that samples random
points close (within a given radius σ2) to a previously computed FBA optimum (see
Appendix B).
Figure 4·5: The maximal value of the biomass coefficient cbiomass,
found by invFBA and subsequent Objective Variability Analysis
(OVA), is plotted as a function of the level of noise (σ2) in FBA-
simulated flux data for E. coli. These FBA-simulated fluxes are pro-
duced using maximization of biomass production as the objective func-
tion. Thus, a value of cbiomass close to unity in OVA indicates that
invFBA recovers the original objective. As the levels of noise increases,
however, the capacity of recovering the original objective is highly re-
duced.
As shown in Fig. 4·5, as the noise approaches zero, invFBA solutions converge to
having as main component the growth maximization objective. As the magnitude of
the noise increases, the maximum possible value for the biomass reaction component
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of the objective decays further and further away from unity, with a major downshift
at the point where the noise level is between 1% and 10% relative to the flux norm.
At that point, the correlation is quickly lost, meaning that the information carried
by the noisy fluxes is not informative of the original objective any more.
4.3.3 Inference of a Linear Objective Function with Time-dependent
Fluxes
After testing the performance of invFBA on exact or noisy flux distributions simulated
by FBA, we took a first step towards employing invFBA for the analysis of experimen-
tal data. In particular, we applied invFBA to genome-scale metabolic fluxes inferred
from a combination of experimentally measured gene expression data and stoichiomet-
ric modeling. In particular, researchers inferred putative time-series flux vectors from
time-series gene expression data at different stages of growth by Shewanella oneiden-
sis under aerobic, carbon-limited conditions (Collins et al., 2012). The method used
for that analysis (temporal expression-based analysis of metabolism, TEAM (Collins
et al., 2012)), extended a prior approach (Blazier and Papin, 2012) by penalizing the
cost of maintaining flux through a reaction with low gene expression. In TEAM, in
contrast to prior methods, the penalty, different for each gene, was estimated based
on a large compendium of gene expression data. Like many other FBA-gene expres-
sion integration methods, TEAM does not use a biologically motivated pre-assumed
objective function, but rather maximizes consistency with measured gene expression
data. Thus, fluxes inferred through TEAM correspond to the outcome of a heuristic
approach for the interpretation of expression data in terms of metabolic fluxes, but do
not assume any prior knowledge on the metabolic objective of the cell. We should em-
phasize that, as described recently (Machado and Herrg˚ard, 2014), integration of gene
expression data to help predict fluxes is still problematic, partly due to the nontrivial
relationship between mRNA and protein levels (Taniguchi et al., 2010). However,
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Figure 4·6: Metabolite secretion flux (dashed line), inferred from ex-
perimental data through the TEAM approach, and maximum coeffi-
cient of the pyruvate secretion flux in the objective function (full line),
as predicted by invFBA (through OVA), are plotted as a function of
time. Metabolite and gene expression data come from time-dependent
measurements performed during batch aerobic growth of the bacterium
S. oneidensis on lactate. The secreted metabolites are pyruvate in
Fig. 4·6a, glycolate in Fig. 4·6b, and acetate in Fig. 4·6c. Positive
fluxes reflect secretion of the metabolite in question, while negative
fluxes reflect uptake.
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in the context of the current work, the TEAM-inferred dataset gives the unique op-
portunity of obtaining putative objectives from genome-scale fluxes that reflect the
metabolic effort of the bacterium as it undergoes changes throughout batch growth.
As in the previous case of model-generated fluxes, the inverse problem admits a large
space of possible solutions, i.e., maximally sparse objective functions that could give
rise to the observed fluxes. Rather than providing specific arbitrary choices of objec-
tives within the possible range, we report the outcome of OVA, as described above.
Among all possible components of the identified objectives, we highlight the ones that
can be compared directly with nontrivial experimental flux measurements, e.g., pyru-
vate secretion or uptake. The scope of OVA, or, more precisely, the reactions it can
include in the objective function, was accordingly confined to exchange reactions. As
seen in Fig. 4·6a, the largest pyruvate secretion component of the objective function
(as computed by OVA) at different time points recapitulates the experimentally de-
tected accumulation of pyruvate in the external medium, previously hypothesized to
be the outcome of overflow metabolism (Vemuri et al., 2006). The same trend holds
for glycolate (Fig. 4·6b) and acetate (Fig. 4·6c), although invFBA predicts optimiza-
tion of acetate secretion at several time points leading up to the renewed secretion of
acetate at 33 h. Applied to genome-scale fluxes obtained at each sample along the
growth curve, the integer-programming variant of invFBA identified biomass produc-
tion as the objective function at all time points. Optimization of biomass production
agrees with these flux distributions originating from a growing S. oneidensis culture
(Collins et al., 2012). These results lend confidence to the capacity of invFBA and
OVA to correctly capture essential features of flux datasets. At the same time it high-
lights the importance of being cautious in the interpretation of objective functions,
as a large component of the objective (e.g., pyruvate secretion) cannot be necessarily
ascribed to a specifically evolved metabolic trait, and may rather be the outcome of
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undesirable overflow metabolism.
4.3.4 The Inference of Linear Objective Functions in E. coli Strains that
Underwent Long-term Evolutionary Experiments
The most interesting application of invFBA is the inference of objective functions for
microbial species and environments for which direct flux measurements are available
and important questions on adaptation and optimality are at stake. An excellent
example of this scenario is the availability of recently measured metabolic flux ra-
tios (Harcombe et al., 2013) for some of the E. coli strains that underwent long-term
experimental evolution in the Lenski Lab. These strains were evolved for 50,000 gener-
ations in glucose minimal medium, leading to important observations and discoveries
on how adaptation works (Beg et al., 2012), (Vemuri et al., 2006), (Maddamsetti
et al., 2015), and (Wiser et al., 2013). The reported flux ratios can be converted to
flux vectors compatible with the stoichiometric constraints (see Appendix C).
The previous FBA analysis of metabolic activity in these strains has suggested that
objective functions other than standard biomass flux maximization may best describe
their evolutionary trajectory (Harcombe et al., 2013). Such analysis, however, only
assessed the capacity of a small set of specific objective functions to lead to correct
fluxes. Using invFBA, it is possible to reanalyze these flux data in an unbiased way,
and characterize the space of objective functions compatible with the observations.
A particularly striking feature of the flux data was the fact that six of the strains
(five evolved and the ancestral) show comparatively low levels of acetate secretion
(or, equivalently, high levels of glucose oxidation), as illustrated in Fig. 4·7A.
Upon applying invFBA to the complete set of measured flux data, we found, as
in the aforementioned case studies, an infinite set of possible solutions, i.e., a convex
polyhedral set of objective functions. Each of these objective functions if used in
FBA could give the observed fluxes as an optimal solution (one of many alterna-
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Figure 4·7: (A) Experimental measurements (by (Harcombe et al.,
2013)) of acetate excretion and glucose uptake for the ancestral (red
star) and evolved (blue and red dots) E. coli strains from Lenskis long-
term evolutionary experiment. The red and blue colors are used here
to highlight two distinct metabolic regimes that different strains seem
to cluster around. (B) A projection (onto a two dimensional subspace)
of the set of objective functions compatible with experimentally mea-
sured fluxes. The graph is obtained through a two-dimensional version
of OVA: for each possible value of the growth flux coefficient of the ob-
jective function (cBiomass), one can find the minimal and maximal value
of the objective function coefficient for the respiratory flux (cRespiration),
obtaining areas that correspond to objective functions compatible with
the measured fluxes. Such regions can be computed for the ancestral
and all evolved E. coli strains. The strains corresponding to the dif-
ferent metabolic regimes (blue and red dots in (A)) map onto different
regions in the space of objectives, labeled with similar colors.
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tive optima). Interestingly, the objective function consisting of only maximization
of growth flux is not part of any of these sets (neither for the ancestral, nor for the
evolved). Using OVA, one can find the maximal possible contribution of the growth
flux in the objective function. While OVA provides ranges for the contributions to
the objective by individual fluxes, it does not give any information on correlations
and tradeoffs between the different flux components in the objective function. Visu-
alization of the whole space of possible objective functions identified by invFBA is
possible only upon reducing somehow the dimensionality. As illustrated in Fig. 4·7B,
this can be achieved by projecting the space of possible optimal objectives onto a
two-dimensional plane whose components are two specified biologically interesting
fluxes. Upon visualizing this space in the plane of growth vs. respiration flux, again
two sets of strains readily emerge, corresponding to the low- and high- respiration
strains shown in Fig. 4·7B. For the same objective coefficient in the growth reaction,
the low-acetate secreting strains have a lower maximal coefficient for respiration in
the objective. This means that, despite the freedom of choice of objectives compatible
with the experimental data, the signatures of how different fluxes may have adapted
is still readable from the specific boundaries of the space of feasible objectives. Our
analysis captures the dichotomy observed at the level of acetate and glucose trans-
port fluxes, and suggests that the low acetate-excretion strains may be interpreted as
having a higher maximization of respiration.
4.3.5 The Inference of a Quadratic Objective Function with Time Series
Fluxes
We next test invFBA on metabolic fluxes simulated by TEAM (Collins et al., 2012)
data, assuming the objective function is quadratic in this case. TEAM avoids as-
suming objective functions in favor of maximizing consistency with measured gene
expression data.
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In this experiment, we assume that the objective function is quadratic. As we
mentioned in problem (4.12), we assume that the cell attempts to achieve its optimal
performance while keeping the least distance from the previously observed state. The
stoichiometric matrix S ∈ R713×870 is available and 15 flux vector samples were ob-
served sequentially during the cell’s growth period. We applied our invFBA approach
(4.17) on these 15 observed flux vectors sequentially to recover the parameters in the
objective functions. The partial parameter values are shown in Table 4.4.
Table 4.4: Inferred parameter values.
Reaction name value β value
t=1 ’B-E’ 0.7175
t=2 ’N-A-D-G-E’ -0.4051 1.01E-12
t=3 ’B-E’ -0.7615 4.73E-07
t=4 ’B-E’ -0.2788 1.59E-11
t=5 ’N-A-D-G-E’ -0.4350 2.50E-12
t=6 ’B-E’ -0.9205 1.21E-10
t=7 ’B-E’ -0.9198 6.27E-10
t=8 ’B-E’ -0.9094 3.71E-10
t=9 ’B-E’ -0.7733 1.54E-07
t=10 ’B-E’ -0.7226 4.98E-07
t=11 ’B-E’ -0.9072 6.90E-11
t=12 ’B-E’ -0.9194 1.03E-10
t=13 ’B-E’ -0.7175 3.12E-07
t=14 ’B-E’ -0.7871 7.79E-07
t=15 ’B-E’ -0.7640 7.18E-07
More specifically, we applied the invFBA method (4.8) and (4.9) on the first sam-
ple and the InvFBA method (4.17) on the remaining 14 samples. In the second and
the third columns, we report the reaction names of the largest elements in c and their
values. ‘N-A-D-G-E’ represents the reaction ‘N-Acetyl-D-glucosamine exchange’ and
‘B-E’ represents the reaction ‘Biomass Equation’. In the fourth column, we list the
values of β in problem (4.12) for different samples. We note that the dominant objec-
81
tive function still corresponds to maximizing the biomass reaction flux. When t = 2
and t = 4, the objective function becomes equivalent to maximizing the N-Acetyl-D-
glucosamine exchange rate. While surprising at first, it is intuitive considering that
to maximize growth rate it suffices to maximize its limited nutrient. We also observed
that the values of β are very small, which suggests that the effect of the quadratic
term in the objective function is minimal. The observations are consistent with the
TEAM simulation that measured samples during the cells growth period.
4.3.6 The Inference of a Kernelized Objective Function on E. coli Data
The E. coli model iAF1260 (Feist et al., 2007) has 3 different sizes: small size (24
metabolites and 32 reactions), midsize (65 metabolites and 84 reactions) and large
size (1039 metabolites and 2077 reactions). In this example, we test invFBA method
(4.22) on midsize model. To test the ability of invFBA to recover a non-parametric
objective function and to evaluate the performance conveniently, we formulate the
forward FBA problem as:
minx∈F Z(x) = minx∈F(−xbio + x′Σx), (4.23)
where the objective function is to maximize the biomass growth rate and to minimize
the weighted least square fluxes. Biologically, the second term aims at reducing
internal flux circles. In problem (4.23), it is easy to compute the gradient of the
objective function which is ∇Z(xi) = −ebio + 2Σx, where ebio represents the unit
vector with 1 corresponding to the biomass growth reaction flux. The simulation
process to infer the non-parametric objective function is shown in Fig. 4·8. In this
simulation, we choose Σ = 10 × I, and we simulate 40 (N = 40) noisy but feasible
samples which we use as inputs to invFBA method (4.22). In this simulation process,
a more complicated objective function is chosen than the one in (4.23). To validate
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the performance, we compute the Pearson correlation coefficient between the actual
gradient vector ∇Z(xi) and the inferred gradient vector ∇Zˆ(xi) at xi, i = 1, . . . , 40.
IAF1260 Model Theoretical fluxes x*
FBA 
Simulation
Noisy  fluxes xi
Inferred gradient vector                 
Add Noise
InvFBA
Correlation  coefficient
between    Z(xi) and              
Validation
Objective function   Z(x) 
 and its gradient     Z(x)
Z^(xi)Z^(xi) 
Figure 4·8: Simulation flowchart for the inference of a nonparametric
objective function.
We plot the Pearson correlation coefficients for each sample point in Fig. 4·9.
In this simulation, we tested RBF kernel, polynomial kernel and linear kernel. The
linear kernel has the best performance. We can see that the inferred gradient vector
is highly consistent with the theoretical gradient vector at those sample points.
4.4 Conclusions
Motivated by the need to understand how cells organize their metabolic networks,
we have developed an inverse optimization framework to recover cellular objective
functions from observed metabolic reactions fluxes. Within this framework, we intro-
duced three different methods corresponding to a linear objective function, a quadratic
objective function, and a non-parametric objective function, respectively. In each of
these cases, we provided a tractable formulation of the inverse problem and numerical
examples to validate our method.
If the objective function is linear or quadratic, our invFBA method results in
a linear programming problem. Simulation results illustrate that invFBA can suc-
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Figure 4·9: Performance evaluation of the nonparametric objective
function.
cessfully recover the cellular objective functions and provide biological insight. If
the objective function is too complicated to describe parametrically, we developed a
non-parametric approach to infer its gradient. To that end we leveraged kernel meth-
ods. The corresponding inverse problem becomes a convex quadratic programming
problem.
The proposed inverse optimization framework offers a way to infer cellular ob-
jective functions from experimental measurements and increase confidence in silico
predictions.
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Chapter 5
Optimal Allocation of Metabolic
Functions among Organisms in a
Microbial Ecosystem
Cellular metabolism is comprised of a complex network of biochemical reactions,
which collectively provide every living cell with energy currency and building blocks
for maintenance and reproduction. Microbial organisms can display a broad diversity
of metabolic functions, which combine the ability to endogenously produce specific
molecules from precursors, with a vast array of specialized transport capabilities.
In microbial communities, each microbial species may secrete into the environment
metabolites that other organisms may be able to use as precursors, potentially giving
rise to cross-feeding interactions. Furthermore, different organisms may compete
for environmentally available common resources. These metabolic interdependencies
form complex and poorly understood ecological networks, likely to play a key role
in the dynamics of microbial communities. In parallel to trying to understand the
interactions and dynamics in natural communities, there has been rising interest
in the possibility of designing engineered communities for a number of applications,
including human health (Cho and Blaser, 2012), waste water treatment (Daims et al.,
2006) and production of biofuels (Shong et al., 2012).
Despite the growing availability of experimental data for a diverse range of com-
plex natural microbial communities, the full characterization and understanding of
these communities is still a challenge (Zomorrodi and Segre`, 2016). To solve this prob-
85
lem, efficient computational techniques and mathematical modeling tools are required.
In recent years, there has been an incredible development of techniques specifically
aimed at trying to predict computationally the metabolic activity of microbial sys-
tems and communities. In particular, one can view genome-scale and ecosystem-level
metabolism as a resource allocation problem. Under a steady-state approximation,
this problem can be efficiently addressed using linear programming, as done by Flux
Balance Analysis (FBA) (Edwards et al., 2001). In the FBA formulation for a single
species, one typically uses linear optimization to identify the set of fluxes that maxi-
mize a cellular objective (e.g., growth) subject to constraints capturing mass balance
of each metabolite and bounds that reflect the composition of the growth medium.
In this chapter, inspired by previous work on ecosystem-level FBA (Zomorrodi
and Segre`, 2016; Khandelwal et al., 2013; Klitgord and Segre, 2010; Stolyar et al.,
2007; Zomorrodi and Maranas, 2012), we focus on metabolic resource allocation in
a microbial community, and set the stage for asking questions about how different
metabolic reactions may be partitioned between different species in order to achieve
a certain community-level goal. We formulate the problem as a Mixed Integer Linear
Programming (MILP) problem inspired by FBA and our recently proposed Inverse
FBA method (Zhao et al., 2015).
The remainder of the chapter is organized as follows. In Section 5.1, we define
the problem mathematically and formulate it as an MILP problem. In Section 5.2,
we test our method on an artificial microbial community containing two different toy
species and assess the method’s effectiveness. In Section 5.3, we apply our method to
a community of two simplified bacteria and evaluate their ability to co-exist. Finally,
concluding remarks and discussions appear in Section 5.4.
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5.1 Problem Formulation
5.1.1 Community-level Flux Balance Analysis
We introduce a “universal stoichiometric matrix,” denoted by S, which expresses
mass balance for all possible reactions in a microbial community irrespective of the
organism they belong to. Specifically, S ∈ RM×N where M = Me + Mi represents
the number of distinct metabolites and N = Nu +Ne +Ni represents the number of
distinct reactions. The M distinct metabolites consist of two types: Me external and
Mi internal metabolites. The external metabolites exist in the shared extracellular
environment of all organisms and the internal metabolites are intracellular. There
are 3 different types of reactions: Nu uptake reactions, Ne exchange reactions and
Ni internal reactions. The availability of nutrients (external metabolites) from the
environment is encoded in the uptake reactions. With exchange reactions, organ-
isms transport these metabolites between their intracellular compartment and the
extracellular environment. Internal reactions take place among internal metabolites.
Assuming that the community consists of K different species, we use Sk, k =
1, . . . , K, to denote the (individual) stoichiometric matrix of species k. This is the ma-
trix that expresses mass balance constraints for all reactions utilized by the metabolic
network of that species. The columns in Sk are a subset of the columns in S. The
matrices Sk may have identical columns (reactions) if more than one species use the
same reaction. Without loss of generality, the structure of S is shown in Fig. 5·1.
Given the matrix S and the number of species K, our goal is to design the individual
stoichiometric matrices Sk that render each species and the community viable, that
is, satisfying appropriate optimality criteria.
In order to formulate the design problem, we first reformulate the universal stoi-
chiometric matrix S to construct putative stoichiometric matrices for each species in
the community (Klitgord and Segre, 2010). In particular, we construct a community
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External 
Metabolites
Internal 
Metabolites
Uptake 
Reactions
Exchange 
 Reactions
0
0
Internal
 Reactions
Figure 5·1: The structure of the universal stoichiometric matrix S.
Block Su represents the set of uptake reactions used to absorb nutrients
from the environment. Blocks [Se1; Se2] represent the set of exchange
reactions between external and internal metabolites. Si represents the
set of internal reactions among internal metabolites.
stoichiometric matrix Sc whose structure is shown in Fig. 5·2. The block matrices Su,
Se1, and Se2 in Sc are consistent with those in S. Organisms in the community share
the same nutrients and uptake reactions. Because there are K organisms in the com-
munity, we replicate the block [Se2,Si] that includes exchange reactions and internal
reactions K times and diagonally arrange them in Sc. This arrangement represents
the process according to which organisms absorb the nutrients via the same uptake
reactions and then allocate them to individual organisms in the community.
After obtaining the internal metabolites via the exchange reactions, internal reac-
tions take place inside each organism. This construction leads to a community stoi-
chiometric matrix Sc ∈ RMc×Nc , where Mc = Me +KMi and Nc = Nu +K(Ne +Ni).
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Notice that Sc has one block column for uptake reactions (Nu columns) and K block
columns (of dimension Ne + Ni), one for each organism, including all exchange and
internal reactions.
To capture design choices, we introduce a binary putative vector t = (t1, · · · tNc),
where ti ∈ {0, 1} is a binary variable, indicating whether the i-th reaction is included
or not in the corresponding organism (cf. Fig. 5·2). With t and Sc available, we can
partition Sc to K individual matrices, Sk, by removing columns j with tj = 0.
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Internal 
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...
times duplicate
times
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t* 1st Kth...
Figure 5·2: The structure of the stoichiometric matrix for the whole
community Sc ∈ RMc×Nc .
If Sc and t are known, we can formulate the FBA problem to predict the flux
distribution vector in the entire community as:
maxx c
′x
s.t. Scx = 0,
diag(t)xlb ≤ x ≤ diag(t)xub,
(5.1)
where c ∈ RNc corresponds to the community objective (e.g., maximizing the total
89
biomass growth rate, maximizing the total uptake rate of a limited nutrient, etc.
(Sauer et al., 1998)) and xub and xlb are upper and lower bounds on fluxes. The
constraints diag(t)xlb ≤ x ≤ diag(t)xub guarantee that the flux of a reaction that
is not included in an organism is set to 0. Problem (5.1) is a linear programming
problem and it can be solved efficiently. The optimal solution of (5.1), denoted by
x∗, represents the flux vector for the entire community.
We now write another linear programming problem which, as we will see, reduces
to the dual of (5.1) when all the non-active (with a corresponding tj = 0) reactions j
and their fluxes xj are removed from (5.1).
minp,q1,q2 q
′
2xub − q′1xlb
s.t. Sc′p− q1 + q2 − c− L(1− t) ≤ 0,
Sc′p− q1 + q2 − c + L(1− t) ≥ 0,
q1,q2 ≥ 0,
q1,q2 ≤ Lt,
(5.2)
where p, q1 and q2 are dual variables and L is a sufficiently large constant. The
role of L is to affect the dual feasibility constraints. The primal variable xi in (5.1)
corresponds to the ith dual constraint in −L(1− t) ≤ Sc′p−q1 + q2− c ≤ L(1− t).
For the reactions included in the corresponding organism we have ti = 1 for i in some
index set I. For these i ∈ I, the corresponding dual constraint becomes [Sc′p]i −
q1i + q2i − ci = 0. For those reactions j, however, which are not included in the
corresponding organism (tj = 0, j 6∈ I), the corresponding dual constraint becomes
−L ≤ [Sc′p]j − q1j + q2j − cj ≤ L, which is trivially satisfied for a large enough L.
Similarly, the dual variables q1 and q2 correspond to the lower and upper bounds on
x in (5.1). If xi is non-zero (ti = 1), q1i and q2i are both non-negative and can take
arbitrarily large values bounded by the large constant L. If, however, xj is set to zero
(tj = 0), then q1j and q2j are set to 0 as well to avoid an unbounded objective value
in (5.2).
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5.1.2 Community Stoichiometric Partitioning
In practice, the putative vector t is unavailable. In fact, identifying t is our primary
goal in this chapter. Based on the analysis of the community-level FBA and the
corresponding dual problem, the feasible set of t, denoted by F can be represented
by the following constraints:
Scx = 0,
x ≥ diag(t)xlb,
x ≤ diag(t)xub,
Sc′p− q1 + q2 − c− L(1− t) ≤ 0,
Sc′p− q1 + q2 − c + L(1− t) ≥ 0,
q1,q2 ≥ 0,
q1,q2 ≤ Lt,
ti ∈ {0, 1},
c′x = q′2xub − q′1xlb.
(5.3)
These constraints capture primal feasibility, dual feasibility and strong duality con-
ditions, respectively. Other than F , additional regularization constraints on t are
necessary to obtain a biologically meaningful solution. Specifically, we impose
tmin ≤ Rt ≤ tmax, (5.4)
where R ∈ RMr×Nc is a regularization matrix. The number of rows Mr depends on
the number of regularization constraints we wish to introduce. Such constraints can,
for example, impose upper and lower bounds on the number of reactions active in
each organism, and/or enforce upper and lower bounds on the number of repeated
reactions in different organisms (hence, controlling for community diversity and ro-
bustness). The regularization constraints enable us to partition the community (Sc)
into individual species (Sk) that are biologically meaningful.
The problem of identifying t can now be formulated as the following Mixed Integer
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Linear Programming (MILP) problem:
maxx,p,q1,q2,t f(x,p,q1,q2, t)
s.t. x,p,q1,q2, t ∈ F ,
tmin ≤ Rt ≤ tmax,
(5.5)
where f(·) is a global linear objective function. Relevant objective functions could
include maximization of the total uptake rate of some nutrients or maximization of
the total biomass growth rate. By solving problem (5.5), we can obtain the putative
vector t∗ and the flux distribution x∗ for the entire community. Then, we can partition
Sc into a set of Sk stoichiometric matrices, one for each species k = 1, . . . , K, based
on t∗.
5.2 An Artificial Toy Model
In this section, we will demonstrate the use of our method with a very simple micro-
bial community toy model consisting of two different organisms (Klitgord and Segre,
2010). In particular, we first analyze the community-level FBA for this model and we
then validate our method by comparing the reaction partition we obtain with ground
truth.
5.2.1 Model Description
The metabolic networks of the two individual species are depicted in Fig. 5·3. The
two species share the same environment, the same metabolites (X, Y, Z), the same
uptake secretion properties, and the same usage of precursors to produce biomass.
They differ, however, in their internal metabolic reactions (R1 and R2). The arrows
in Fig. 5·3 represent reactions. The boxes represent distinct (intracellular) metabolic
compartments. This level of compartmentalization is usually sufficient to appropri-
ately model individual species.
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X Y XZ
X + Y + Z X + Y + Z
Z
Biomass 2 Biomass 1
R1: R2:
EX
Organism 2 Organism 1
Figure 5·3: The structure of the artificial community with two dif-
ferent organisms. Both organisms 1 and 2 uptake the same external
metabolite (EX) from the environment. Organism 2 produces Y only
via R1 and obtains Z from organism 1. Organism 1 produces Z only
via R2 and obtains Y from organism 2. Organisms 1 and 2 have the
same biomass growth reaction which involves X, Y and Z. Organisms
1 and 2 cannot grow without each other.
5.2.2 FBA at the Community Level
The universal stoichiometric matrix S of this model is shown in Fig. 5·4. S ∈ R6×7 is
like a library which contains all possible reactions in this community. Following the
structure in Fig. 5·2, we construct the community stoichiometric matrix Sc ∈ R9×13
shown in Fig. 5·5. The combination of Sc and t mathematically describes the true
topology of the community metabolic network.
With Sc, t, xlb and xub available, we solve the community-level FBA problem
(5.1). The objective is to maximize the sum of biomass growth rates of organisms 1
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Figure 5·4: The universal stoichiometric matrix S. The rows of S
include three external metabolites (EX,EY,EZ) and three internal
metabolites (X, Y, Z). The columns of S include one uptake reaction,
three exchange reactions, and three internal reactions.
Figure 5·5: The community stoichiometric matrix Sc is shown in the
top figure. The binary vector t denotes the ground truth, consistent
with Fig. 5·4. The optimal flux distribution x∗ is shown in the bottom.
To distinguish the internal metabolites in the two organisms, we use
X1, Y 1 and Z1 to denote the internal metabolites in organism 1, and
X2, Y 2 and Z2 for the internal metabolites in organism 2.
and 2 (mathematically xb1+xb2). In the rest of this chapter, we use abbreviations bi to
denote the biomass reactions and fluxes of organism i. The predicted flux distribution
x∗ in steady-state is shown in Fig. 5·5. Both organisms 1 and 2 take the external
metabolite EX with a rate equal to 6. Organism 2 transports the external metabolite
EX to the internal metabolite X with a rate of 6 and generates Y with a rate of
4. Organism 1 transports EX to the internal metabolite X with a rate of 6 and
generates Z with a rate of 4. At the same time, Y is transported from organism 2 to
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1 through EY with a rate of 2 and Z is transported from organism 1 to 2 through EZ
with a rate of 2. With these reactions taking place simultaneously, both organisms
can grow with a rate of 2. We note that organism 2 needs to feed organism 1 with
metabolite Y and organism 1 needs to feed organism 2 with metabolite Z for both
of them to grow. It is clear that neither organism can grow on its own. These fluxes
obtained from FBA provide us with the ground truth to validate our method in the
next subsection.
5.2.3 Identification of the Putative Vector t
In the previous subsection, we assume the availability of t for solving the community-
level FBA problem. Next, we assume that the metabolic network structure of each
individual organism is unknown and the putative vector t is not available. We would
like to identify t based on available S, xlb, xub and the regularization constraints on t.
We apply the formulation (5.5) to obtain t∗. In this case, we impose the regularization
constraints on t described in the sequel.
First, we enable the biomass reactions for each organism, which implies (5.6), and
set the lower bounds of xb1 and xb2 to 1.
tb1 = 1, tb2 = 1. (5.6)
The interactions between organisms 1 and 2 must produce EY and EZ in the growth
medium. For this reason, we impose constraints (5.7).
tYex1 = 1, tYex2 = 1, tZex1 = 1, tZex2 = 1. (5.7)
We also impose in (5.8) bounds on the number of enabled reactions, where the lower
bound is determined by (5.6) and (5.7) and the the upper bound is determined by
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the number of columns in Sc.
6 ≤
13∑
i=1
ti ≤ 13. (5.8)
As the global objective function in (5.5) we select f(x,p,q1,q2, t) = xb1 + xb2,
which seeks to maximize the total biomass growth rate in this community. The
solutions (t∗ and x∗) are shown in Fig. 5·6. The inferred t∗ is identical with the
ground truth and the flux distribution x∗ under steady-state is consistent with the
flux vector in the bottom of Fig. 5·5. Therefore, our method can successfully identify
the structure of each organism and predict the steady-state flux distribution for the
entire community simultaneously.
Figure 5·6: The results of identifying t∗ and the corresponding flux
vector x∗. They are consistent with the ground truth in Fig. 5·5.
5.3 A Simplified Bacterial Community
5.3.1 Model Description
In this section, we apply our method to a community with two simplified bacterial
networks. We start by assuming that two identical bacterial species are present in a
community, but constrain the number of metabolic reactions available in each species.
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The fully functional bacterial model is a generic bacterial core metabolic network from
(Covert et al., 2001) which contains 7 external and 12 internal metabolites involved
in 28 reactions, including 7 uptake reactions, 7 exchange reactions, and 14 internal
reactions. The corresponding universal stoichiometric matrix S ∈ R19×28 is shown in
Fig. 5·7. We apply FBA with the objective of maximizing the biomass growth rate
of this single bacterial model and the corresponding flux distribution x∗ is shown at
the bottom of Fig. 5·7. The maximum biomass growth rate is 3.63 under the current
growth conditions.
Figure 5·7: The universal stoichiometric matrix S and the correspond-
ing flux vector by maximizing the biomass growth rate for an individual
bacterial model from (Covert et al., 2001) under the current growth
conditions.
5.3.2 Community Analysis
In this test, we put two partially functional bacteria in the same growth medium. To
analyze the relationship between the total biomass growth rate and the number of
active internal reactions in each strain, we use the following objective function:
f(x,p,q, t) = xb1 + xb2 − λ
2∑
j=1
∑
j∈Rj
tj, (5.9)
where Rj represents the set of internal reactions in strain j, j = 1, 2, and λ is a
positive tunable constant used to capture the trade-off between total biomass growth
rate and the sparsity of each individual bacterial strain. In this case, to guarantee the
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growth of both strains 1 and 2, we set the lower bounds of the corresponding fluxes
to 0.5. Then, we apply different values of λ and the corresponding results are shown
in Table 5.1.
Table 5.1: Biomass growth rate vs. the number of active reactions in
the community.
λ = 0 λ = 1 λ = 10 λ = 100 λ = 1000
Total biomass
growth rate 3.63 3.16 3.16 1.23 1.05
# of all reactions 34 36 33 31 29
Ni in strain 1 9 10 9 10 9
Ni in strain 2 9 9 9 6 8
When λ = 0, the total biomass growth rate achieves the maximum value (3.63),
which is is consistent with the FBA result in Fig. 5·7. The fully functional bacterial
organism contains 12 internal reactions, however, there are only 9 internal reactions
in each strain 1 and 2. This implies that not all internal reactions are required to
maintain the maximum biomass growth rate. As λ increases, the total biomass growth
rate decreases and the total number of reactions decreases as well. When λ ≥ 1000,
the total biomass growth rate achieves its lower bound (1.0), and the total number
of reactions is reduced compared to λ = 0.
In order to better visualize the community of two bacterial strains (obtained with
λ = 0) and the corresponding flux distribution, we use the network visualization
software VisAnt (Hu et al., 2004) to draw Fig. 5·8. VisAnt has the unique capability of
concurrently visualizing intracellular metabolism and ecological metabolite-mediated
interaction networks. Note that none of the organism identified as a solution to
this problem is able to produce all biomass components by itself. As seen in the
figure, one of the two resulting networks (right) utilizes oxygen available from the
external environment, and a molecule (F) secreted by the other organism to produce
hydrogen through redox reactions. The other organism (left) utilizes multiple carbon
sources, and the hydrogen transferred from the partner organism, to run most of the
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metabolic activity. Interestingly, organism 1 does not require the uptake of oxygen.
Note that, as required by the constraints imposed in the algorithm, both organisms
have to produce no less than a minimal amount of biomass. While, this specific toy
example may not have an obvious biological interpretation, or a counterpart in real
communities, it illustrates the power of the algorithm in identifying two syntrophic
cross-feeding species that would be very difficult to design manually.
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Figure 5·8: Visualization of the outcome of our algorithm, applied to
a model of generic bacterial central carbon metabolism from (Covert
et al., 2001). In this case, the algorithm is applied to two organisms
that have the potential to contain all 12 internal reactions found in the
initial network. Yet, the algorithm identifies two distinct species with
fewer internal reactions that perform different tasks, but can collectively
achieve all the metabolic functions necessary for growth.
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5.4 Conclusions
Motivated by the need to interpret how organisms interact in a microbial community,
we have developed an optimization framework to identify the individual metabolic
network of each organism in the community and to predict the resulting flux distri-
butions. We formulated the problem of allocating reactions to organisms as an MILP
problem. We tested the method on both a toy artificial community and a commu-
nity composed of two bacterial organisms with a simplified core metabolism. In both
cases, the method helped us identify the individual metabolic network topologies and
elucidate the interaction between species in the microbial community.
The proposed method provides a meaningful way to analyze and simulate the
combinatorial complexity of metabolite-mediated interactions between multiple or-
ganisms in a microbial community. It also offers a new platform for the rational
design of organisms and communities towards future synthetic ecology applications.
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Chapter 6
Conclusions
We start this chapter by summarizing our current progress and contributions in Sec-
tion 6.1. Then we discuss directions for future work in Section 6.2.
6.1 Summary
In this thesis, we have considered three biomedical problems involving optimization
and control methods: the automated medication dosage control problem, the cellular
objective inference problem and the metabolic function allocation problem.
In the problem of automating medication dosage, we have developed two main
approaches to predict the effect of bivalirudin in cardiac surgical patients. The first
approach is model-free and leverages regularized regression. The second approach
is model-based and constructs a specific model that captures how bivalirudin affects
PTT values. The mathematical models and prediction approaches provide a better
reference to guide the optimal therapy in cardiac patients in need of bivalirudin.
Based on the specific dynamic system model of bivalirudin acting in cardiac surgi-
cal patients, we have developed two methods for synthesizing a controller to regulate
the bivalirudin infusion rate and to induce the effect of bivalirudin within a desir-
able range. The first method assumes that the model parameters are available and
develops a control law that tracks a physician-specified reference output signal. Our
second method considers patients for which past clinical records are sparse and ac-
curate model parameters are not readily available. We have developed an indirect
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control scheme (indirect MRAC) that first estimates the model parameters and then
adapts the corresponding controller based on these estimates. Alternatively, a di-
rect control scheme (direct MRAC) that adapts the controller without estimating the
model parameters first is also developed. Testing of these schemes against actual
patient data from a hospital showed that the direct MRAC is more efficient than
the indirect version. The methods we developed can be seen as key steps toward
automation of dosage decisions in the hospital setting, which can help eliminate er-
rors and neutralize the inexperience of residents who are currently responsible for
these decisions. In addition, such mathematical ideas and methods may be useful
to test medication dosing strategies and may provide a mathematical mechanism for
development and testing of nomograms.
In the cellular objective inference problem, we have introduced a new theoretical
framework that enables a more formal, efficient and systematic analysis of the possible
objective functions. The framework is compatible to linear objectives, to quadratic
objectives, and to non-parametric convex objectives. The invFBA approach we devel-
oped constitutes a specific instance of a broader, powerful, and still highly unexplored
avenue for posing and solving inverse optimization problems. The relevance of our al-
gorithm may extend beyond the realm of metabolic network modeling, for example to
game-theoretic models of traffic equilibria in transportation problem and price-setting
games in economics.
In the problem of allocating metabolic functionality to distinct organisms living
together, which can be used to interpret how organisms interact in a microbial com-
munity, we have developed an optimization-based framework to identify the metabolic
network structure of the individual organisms and to predict the flux distribution for
the whole community. This problem has been formulated as a mixed integer linear
programming problem. We tested the method on an artificial community and a com-
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munity of two simplified bacteria. For both cases, the method helped us identify the
individual network topology and understand interaction behaviors in the microbial
community. The proposed method provides a meaningful way to analyze and simulate
the combinatorial complexity of metabolite-mediated interactions between multiple
organisms in a microbial community. It also offers a new platform for the rational
design of organisms and communities towards future synthetic ecology applications.
6.2 Future Works
Continuing with the metabolic functionality allocation problem, we already proposed
a Mixed Integer Linear Programming (MILP) based approach and tested it on two
simple models. However, the real microbial community includes a large number of
organisms. Therefore, we need to perform more assessments of the method’s effective-
ness and scalability before applying it to a more realistic microbial community model.
The first necessary assessment is to evaluate our method on an artificial community
which includes more than two organisms.
In addition to the large number of organisms in the real microbial community, the
complicated metabolic network structure is another challenge for our current method.
A full stoichiometric matrix of an organism may include more than thousands of
metabolites and reactions. Because our current method is based on mixed integer
linear programming, the computational task may become very heavy in the large scale
case. For this reason, we should evaluate the performance (e.g., optimality, running
time, etc.) of our method in the large scale case. Furthermore, an appropriate
relaxation of the current method is required in order to ensure scalability to large
networks.
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Appendix A
LASSO Version of InvFBA
We have already discussed that FBA in practice is used with an additional sparsity-
inducing `1-norm regularization (cf. (4.2)). This motivates the use of a similar regu-
larization in the context of InvFBA. Alternatively, a convenient way to combine the
least optimality gap and sparsity of objective function is to formulate the invFBA
problem as:
min
i,pi,qi1,q
i
2,c
∑N
i=1 i + λ
∑n
j=1 |cj| (A.1)
s.t.
∑n
j=1 cj = 1,
pi
′
S− qi′1 + qi
′
2 = c
′, ∀i,
qi
′
2vub − qi
′
1vlb − i = c′xi, ∀i,
q1,q2 ≥ 0, ∀i,
i ≥ 0, ∀i,
where λ is some tunable non-negative constant. This formulation is reminiscent of
the LASSO-type regression (Hastie et al., 2009).
One can interpret non-zero elements in optimal solutions c of (A.1) as correspond-
ing to important metabolic fluxes that are critical in the FBA optimization context
and provide a minimal description of the cellular objective function. Notice that for-
mulation (A.1) is a linear programming problem, just like the forward FBA problem,
which is not in general true for inverse optimization problems (Bertsimas et al., 2013).
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Appendix B
Noise Generation
In order to generate simulated feasible flux vectors around a defined point, containing
a given amount of noise, we devised the following optimization problem:
max
xi
r′xi (B.1)
s.t. Sxi = 0,
vlb ≤ xi ≤ vlb,
||xi − x∗|| ≤ σ2,
where r is a random objective function, xi is the noisy flux distribution, x
∗ is the
pre-computed optimal flux distribution, and σ2 denotes the largest Euclidean dis-
tance between optimal flux and noisy flux. Changing the value of σ2 yields different
magnitudes of noise.
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Appendix C
Inference of Fluxes from Experimentally
Measured Branching Ratios
To apply the invFBA algorithm and infer the objective function in E. coli strains
that underwent long-term evolutionary experiments (LTEE), we needed to convert
the 13C-labeling raw measurements of flux ratios and uptake/secretion rates into
central carbon metabolism flux values.
The dataset we used is obtained from (Harcombe et al., 2013). This dataset
includes measurements for one ancestral strain (Anc) and ten evolved strains (named,
as in the original paper, A+1, A+2, A+3, A+4, A+5, A−1, A−2, A−3, A−4, A5, A−
6). For each strain, six pathway branch ratios (Ser from glycolysis, PYR though ED
pathway, upper bound of PEP through PPP, lower bound of PYR from MAL, OAA
from PEP, PEP from OAA; see also (Zamboni et al., 2005)) and three external fluxes
(glucose uptake rate, acetate excretion rate and growth rate) are available. All fluxes
are part of a central carbon metabolism model for E. coli with stoichiometric matrix
S. In our formulation, we call Ris (s = 1, · · · , 11; i = 1, · · · , 6) the measured pathway
branch ratio i of strain s and Ejs (s = 1, · · · , 11; j = 1, 2, 3) the measured value of
external flux j of strain s. Each flux ratio Ris can be expressed in terms of the flux
vectors, appropriately weighted by two vectors ai ∈ Rn and bi ∈ Rn:
a′ix/b
′
ix = R
i
s, i = 1, · · · , 6. (C.1)
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These equations can be reformulated as standard linear equations:
Ax = 0, (C.2)
where the ith row of A is a′i − b′iRis, i = 1, · · · , 6. Translating the measured ratios
and external fluxes to a feasible flux distribution for strain s is posed as the following
optimization problem
min ||Axs||2 (C.3)
s.t. Sxs = 0,
Ejs − β · stdjs ≤ xjs ≤ Ejs + β · stdjs, j = 1, 2, 3,
where β is a coefficient determining the feasible range (here, we set β = 1), and
stdjs is the standard deviation of the measurements of external flux j of strain s.
The problem (C.3) is a standard quadratic programming problem yielding the flux
distribution, which is the closest one to the measured pathway branch ratio and is
consistent with the stoichiometry constraints and external flux measurements. The
problem can be solved efficiently and global optimality can be guaranteed. The
optimal solution xs of (C.3) is the feasible flux distribution for strain s and can be
used to test our invFBA algorithm.
The problem (C.3) is a standard quadratic programming problem yielding the
flux distribution, which is the closest one to the measured pathway branch ratio
and is consistent with the stoichiometry constraints and external flux measurements.
The problem can be solved efficiently and global optimality can be guaranteed. The
optimal solution xs of (C.3) is the feasible flux distribution for strain s and can be
used to test our invFBA algorithm.
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